{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:09 23:24:50.411",
            "Expression": "mesenchymal autologous",
            "NStudiesAvail": 430269,
            "NStudiesFound": 475,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 475,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [
                              "SMART-MS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Receives mesenchymal stem cells at baseline and placebo at 6 months",
                              "Receives placebo at baseline and mesenchymal stem cells at 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: MSCs",
                              "Drug: Saline",
                              "Other: MSCs",
                              "Drug: Saline"
                        ],
                        "ArmGroupLabel": [
                              "Arm A - Crossover with MSCs at baseline and placebo at 6 months",
                              "Arm B - Crossover with placebo at baseline and MSCs at 6 months"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04749667"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [
                              "CSM/FAP/2012"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with prolonged postoperative air leaks"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Implantation of autologous mesenchymal stem cells (CSM) expanded \"in vitro\" and administered directly into the lung suture line"
                        ],
                        "ArmGroupLabel": [
                              "Prolonged postoperative air leaks in risk patients."
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02045745"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Two escalated intrathecal infusions of autologous mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal stem cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02987413"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [
                              "ESTIMATION"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Endocardial Stem cells implantation with Noga system",
                              "Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: PCI and Stem Cells or Placebo injections",
                              "Procedure: PCI and Stem Cells or Placebo injections"
                        ],
                        "ArmGroupLabel": [
                              "Group 1 (PCI+SC implantation)",
                              "Group 2 (PCI+Placebo)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01394432"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.",
                              "The patients who treated with the conventional therapy for urticaria, but not treat with mesenchymal stem cell."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell",
                              "Control patients"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02824393"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)\n\nPharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02570932"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving intra-articular injection of autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous adipose-derived mesenchymal stem cells",
                              "Procedure: abdominal liposuction"
                        ],
                        "ArmGroupLabel": [
                              "Autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03956719"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [
                              "MSC-SCI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01694927"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [
                              "AMSCDRSE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs [AEDs]) and receiving autologous mesenchymal stem cells",
                              "Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "study group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02497443"
                        ]
                  },
                  {
                        "Rank": 10,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dose of infused cells is 10e6 cells/Kg",
                              "The dose of infused cells is 4*10e6 cells/Kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous mesenchymal stem cells from adipose tissue.",
                              "Other: Autologous mesenchymal stem cells from adipose tissue."
                        ],
                        "ArmGroupLabel": [
                              "Low dose autologous mesenchymal cells",
                              "High dose",
                              "Placebo Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01056471"
                        ]
                  },
                  {
                        "Rank": 11,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adult Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02165904"
                        ]
                  },
                  {
                        "Rank": 12,
                        "Acronym": [
                              "MSV-DISC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: Autologous bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSV autologous transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02440074"
                        ]
                  },
                  {
                        "Rank": 13,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .\n\nMSC a day-case 2\u00b70\u00d7106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v.",
                              "Patients with progressive and refractory NMO treated with regular methods"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02249676"
                        ]
                  },
                  {
                        "Rank": 14,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "To study the safety and efficacy of autologous transplantation of bone marrow mesenchymal stem cells in treatment of newly diagnosed patients with T1DM."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous transplantation"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01157403"
                        ]
                  },
                  {
                        "Rank": 15,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Genetic: autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01499459"
                        ]
                  },
                  {
                        "Rank": 16,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All subjects will receive autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01649700"
                        ]
                  },
                  {
                        "Rank": 17,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with spinal cord injury that will undergo laminectomy and autologous mesenchymal cells intralesional injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Single group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02574572"
                        ]
                  },
                  {
                        "Rank": 18,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSC transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00813969"
                        ]
                  },
                  {
                        "Rank": 19,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02482194"
                        ]
                  },
                  {
                        "Rank": 20,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "5\u00d710^6 AD-MSCs",
                              "20\u00d710^6 AD-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03461458"
                        ]
                  },
                  {
                        "Rank": 21,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Fistulizing Crohn's disease"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01157650"
                        ]
                  },
                  {
                        "Rank": 22,
                        "Acronym": [
                              "CP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ASTROSTEM"
                        ],
                        "ArmGroupLabel": [
                              "Astrostem"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03979898"
                        ]
                  },
                  {
                        "Rank": 23,
                        "Acronym": [
                              "CMM-EM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01228266"
                        ]
                  },
                  {
                        "Rank": 24,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Early treatment with mesenchymal stem cells",
                              "Delayed treatment with mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01730547"
                        ]
                  },
                  {
                        "Rank": 25,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will be treated with 1 single dose of IV infusion of autologous bone-marrow derived mesenchymal stem cells (1-2 million cells/kg body weight) and their therapeutic response will be followed over 48 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Open label single arm study"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03778333"
                        ]
                  },
                  {
                        "Rank": 26,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intra bronchial injection, Autologous MSCs transplantation derived bone marrow, 60millions cells, once"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous MSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSCs transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01758055"
                        ]
                  },
                  {
                        "Rank": 27,
                        "Acronym": [
                              "ASD2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: Expanded autologous bone marrow-derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03343782"
                        ]
                  },
                  {
                        "Rank": 28,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Every patient is given 1x106 MSCs per kg infused via liver artery",
                              "autologous bone marrow mesenchymal stem cells transplantation",
                              "autologous bone marrow mesenchymal stem cells transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous bone marrow mesenchymal stem cells transplantation",
                              "Biological: autologous bone marrow msenchymal stem cells transplantation",
                              "Biological: autologous bone marrow mesenchymal stem cells transplantation",
                              "Biological: autologous bone marrow msenchymal stem cells transplantation",
                              "Biological: autologous bone marrow mesenchymal stem cells transplantation",
                              "Biological: autologous bone marrow msenchymal stem cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "autologous bone marrow mesenchymal stem cells transplantation",
                              "mesenchymal stem cells transplantation",
                              "stem cells transplantation"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01854125"
                        ]
                  },
                  {
                        "Rank": 29,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Hyaluronic Acid",
                              "Biological: Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Hyaluronic acid",
                              "Bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01459640"
                        ]
                  },
                  {
                        "Rank": 30,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke",
                              "Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Standard medical care",
                              "Other: Standard medical care",
                              "Biological: Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Standard medical care",
                              "BM-MSCs"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01461720"
                        ]
                  },
                  {
                        "Rank": 31,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 5 x 10^7 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 1 x 10^7 or increased to 1 x 10^8, based on Dose Modification Rules."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03268603"
                        ]
                  },
                  {
                        "Rank": 32,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Within 30 days after extracting bone marrow, autologous bone marrow-derived mesenchymal stem cells is directly injected into the lesion. Then the second cell is injected within 30 days after the first cell injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Cellgram-CLI"
                        ],
                        "ArmGroupLabel": [
                              "2-time injection group : Cellgram-CLI"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02477540"
                        ]
                  },
                  {
                        "Rank": 33,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Adipose Tissue derived MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "AdMSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01643681"
                        ]
                  },
                  {
                        "Rank": 34,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Stress urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells",
                              "Patients with Stress urinary incontinence receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cells",
                              "Other: Standard treatment according to the Clinical protocols",
                              "Other: Standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04446884"
                        ]
                  },
                  {
                        "Rank": 35,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "a single-group, open, investigator-initiated clinical study\n\n: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: autologous adipose derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "a single, open clinical trial"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02338271"
                        ]
                  },
                  {
                        "Rank": 36,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on day 0 and placebo on month 6.",
                              "A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on month 6 and placebo on day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow autologous mesenchymal stem cells transplantation",
                              "Biological: Bone marrow autologous mesenchymal stem cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1",
                              "Arm 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02035514"
                        ]
                  },
                  {
                        "Rank": 37,
                        "Acronym": [
                              "KDD&MSV"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous bone marrow mesenchymal stem cells (MSV)"
                        ],
                        "ArmGroupLabel": [
                              "MSV autologous transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01183728"
                        ]
                  },
                  {
                        "Rank": 38,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention:\n\nAutologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02945462"
                        ]
                  },
                  {
                        "Rank": 39,
                        "Acronym": [
                              "MSCTXT1DM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with Type 1 Diabetes, who will receive Intravenous injection of autologous bone-marrow derived mesenchymal stem cells",
                              "The patients with Type 1 Diabetes, who will receive intravenous injection of normal saline (sodium chloride 0.9%)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous Injection of autologous mesenchymal stem cells",
                              "Other: Intravenous injection of placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells Transplantation",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04078308"
                        ]
                  },
                  {
                        "Rank": 40,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal and intravenous treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously in patients with active multiple sclerosis, failures to respond to other treatments"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection of autologous bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00781872"
                        ]
                  },
                  {
                        "Rank": 41,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Receive a single IV administration of cellular product (Bone marrow mesenchymal stem cells autologous) on Day 0 and placebo infusion on day + 180.\n\nDose: 1-2x10^6 cells/Kg",
                              "Receive a placebo infusion on day 0 and a single administration cellular product on day +180. Dose: 1-2x10^6 cells/Kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Bone marrow mesenchymal stem cells autologous",
                              "Other: Placebo comparator"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01745783"
                        ]
                  },
                  {
                        "Rank": 42,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.",
                              "Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Treated group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02574585"
                        ]
                  },
                  {
                        "Rank": 43,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients who will receive Autologous Mesenchymal Stem Cells from AdiposeTissue by Intrathecal injection of stem cells that will be performed 3 times.",
                              "Patients who will receive Autologous Mesenchymal Stem Cells from Bone marrow by Intrathecal injection of stem cells that will be performed 3 times."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Recipient of AT-MSC",
                              "Recipient of BM-MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02981576"
                        ]
                  },
                  {
                        "Rank": 44,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018871"
                        ]
                  },
                  {
                        "Rank": 45,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intrathecal injection of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018793"
                        ]
                  },
                  {
                        "Rank": 46,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells",
                              "Patients with Urinary incontinence receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cells",
                              "Other: Standard treatment according to the Clinical protocols",
                              "Other: Standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04426643"
                        ]
                  },
                  {
                        "Rank": 47,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "drug name and ingredients : RNL-Vascostem[Autologous adipose tissue derived mesenchymal stem cells] dosage : Intramuscular infusion, 5 x 10e6 cells/kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: RNL-Vascostem\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "RNL-Vascostem\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01302015"
                        ]
                  },
                  {
                        "Rank": 48,
                        "Acronym": [
                              "MESEMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0",
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells",
                              "Suspension media"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01854957"
                        ]
                  },
                  {
                        "Rank": 49,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Clinical case series"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone Marrow Aspiration",
                              "Procedure: Bone marrow mesenchymal stem cell implantation"
                        ],
                        "ArmGroupLabel": [
                              "Single"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00891501"
                        ]
                  },
                  {
                        "Rank": 50,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: normal saline",
                              "Biological: autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "normal saline",
                              "autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00911365"
                        ]
                  },
                  {
                        "Rank": 51,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "25 million mesenchymal stem cells administered intrathecally every 3 months for 4 injections",
                              "25 million mesenchymal stem cells administered intrathecally every 6 months for 2 injections (placebo injections at 3 month and 9 month timepoints)",
                              "Placebo (lactated Ringer's) administered intrathecally every 3 months for 4 injections"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Other: Placebo",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1",
                              "Arm 2",
                              "Arm 3"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05167721"
                        ]
                  },
                  {
                        "Rank": 52,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone marrow aspiration"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01895413"
                        ]
                  },
                  {
                        "Rank": 53,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular administration in early stage patients",
                              "Intrathecal administration in progressive stage patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC-NTF cells transplantation (IM)",
                              "Biological: MSC-NTF cells transplantation (IT)"
                        ],
                        "ArmGroupLabel": [
                              "MSC-NTF cells IM",
                              "MSC-NTF cells IT"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01051882"
                        ]
                  },
                  {
                        "Rank": 54,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects in the S50 cohort will receive one injection of 50 million AMSCs.",
                              "Subjects in the S100 cohort will receive one injection of 100 million AMSCs.",
                              "Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.",
                              "Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "S50",
                              "S100",
                              "M50",
                              "M100"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02805855"
                        ]
                  },
                  {
                        "Rank": 55,
                        "Acronym": [
                              "MESERIC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Type 1 diabetic man\nAged from 18 to 50 years\nHaving a diabetes evolving for at least 10 years\nPresenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot\nPresenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)\nIIEF-5 score less than or equal to 10"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Bone Marrow derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "arm treated with MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03361631"
                        ]
                  },
                  {
                        "Rank": 56,
                        "Acronym": [
                              "EPIC/MSC/IBD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stromal cell"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01659762"
                        ]
                  },
                  {
                        "Rank": 57,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury",
                              "Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "mesenchymal cells&platelet lysate"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02118519"
                        ]
                  },
                  {
                        "Rank": 58,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.",
                              "Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous, Adipose Derived Mesenchymal Stem Cells",
                              "Other: Best Medical Management: Occupational and Physical Therapy",
                              "Biological: Autologous, Adipose Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group 1: AD-MSC Injection",
                              "Treatment Group 2: Best Medical Management"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04520373"
                        ]
                  },
                  {
                        "Rank": 59,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01609283"
                        ]
                  },
                  {
                        "Rank": 60,
                        "Acronym": [
                              "Cellgram-ED"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intracavernous injection of Placebo Oral PDE5-inhibitor can take daily and on demand.",
                              "Single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take daily and on demand."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cellgram-ED"
                        ],
                        "ArmGroupLabel": [
                              "Placebo-Control group",
                              "Injection group: Cellgram-ED"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04594850"
                        ]
                  },
                  {
                        "Rank": 61,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will receive the implantation of autologous mesenchymal stem cell origin of adipose tissue with a dose of 2 x 50 million cells given with a distance of 1 month",
                              "This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord with a dose of 2 x 50 million cells given a distance of 1 month.",
                              "This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord as much as 2 x 50 million followed by 2 x 10cc mesenchymal stem cell secretions from adipose tissue intravenously given at a distance of 1 month."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose Mesenchymal Stem Cell Implantation",
                              "Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation",
                              "Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose MSC Group",
                              "Allogeneic Umbilical Cord MSC Group",
                              "Allogeneic Umbilical Cord MSC and Adipose Secretome Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04876326"
                        ]
                  },
                  {
                        "Rank": 62,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow derived stem cells injected intrathecally to enrolled MS patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01895439"
                        ]
                  },
                  {
                        "Rank": 63,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Adipose Tissue derived MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue Derived MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01643655"
                        ]
                  },
                  {
                        "Rank": 64,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment and mesenchymal stem cells",
                              "Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Other: standard treatment",
                              "Other: standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04432467"
                        ]
                  },
                  {
                        "Rank": 65,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive standard islet transplantation.",
                              "Patients will receive MSCs together with standard islet transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stromal cell"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "autologous mesenchymal stromal cell"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02384018"
                        ]
                  },
                  {
                        "Rank": 66,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01624779"
                        ]
                  },
                  {
                        "Rank": 67,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intrathecal administration of autologous MSC-NP in three doses at three month intervals"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: intrathecal administration of autologous MSC-NP"
                        ],
                        "ArmGroupLabel": [
                              "autologous MSC-NP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01933802"
                        ]
                  },
                  {
                        "Rank": 68,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 patients with mandibular fractures were managed by open reduction and internal fixation, with application of autologous mesenchymal stem cells on the fracture site.",
                              "10 patients with mandibular fractures were managed by open reduction and internal fixation, without application of autologous mesenchymal stem cells on the fracture site."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Application of autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Fractures with Mesenchymal Stem Cells",
                              "Fractures without Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02755922"
                        ]
                  },
                  {
                        "Rank": 69,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.",
                              "The control group received intra-articular injection of sodium hyaluronate one month after operation."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous Adipose-derived Mesenchymal Stem Cell Gel",
                              "Procedure: Extraction of abdominal fat",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose-derived Mesenchymal Stem Cell Gel",
                              "sodium hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03955497"
                        ]
                  },
                  {
                        "Rank": 70,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection to IT (Group 1). After 6 months, 8 patients (group 1A) will be treated with MSC once again in IT, and 8 additional patients (group 1B) will receive a placebo.",
                              "Injection to IV (Group 2). After 6 months, 8 patients (group 2A) will be treated with MSC once again in IV, and 8 additional patients (group 2B) will receive a placebo.",
                              "Placebo at the first injection (group 3). After 6 months, 8 patients (group 3A) will be treated with MSC in IT, and 8 additional patients (group 3B) will be treated with MSC in IV."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "IT- Treated",
                              "IV - Treated",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02166021"
                        ]
                  },
                  {
                        "Rank": 71,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment plus MSC's IV",
                              "Conventional treatment only"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose MSC's"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Derived Mesenchymal Cells",
                              "Untreated"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04352803"
                        ]
                  },
                  {
                        "Rank": 72,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with trophic ulcers received standard treatment and MSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04457037"
                        ]
                  },
                  {
                        "Rank": 73,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection\n\nOther Names:\n\nADSC, mesenchymal cells, stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose derived mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "Adipose derived mesenchymal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02326935"
                        ]
                  },
                  {
                        "Rank": 74,
                        "Acronym": [
                              "MANT3_ASC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05011474"
                        ]
                  },
                  {
                        "Rank": 75,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous transplantation of autologous bone marrow mesenchymal stem cell plus conventional treatment include rehabilitation",
                              "Control group receive conventional stroke treatment that include rehabilitation"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Intravenous stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous stem cell transplantation",
                              "Conventional treatment"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02564328"
                        ]
                  },
                  {
                        "Rank": 76,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow derived mesenchymal stromal/stem cells injection during decompressive surgery in patients with Kienb\u00f6ck's disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MSC transplantation"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02646007"
                        ]
                  },
                  {
                        "Rank": 77,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in group A will receive two autologous AD-MSC administrations on day 0 and day 90 \u00b1 7",
                              "Patients in group B will receive two autologous AD-MSC administrations on day 180 \u00b1 14 and day 270 \u00b1 14"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency",
                              "Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs infusions, then Placebo",
                              "Placebo, then AD-MSCs infusions"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05329662"
                        ]
                  },
                  {
                        "Rank": 78,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation",
                              "Control group receive conventional stroke treatment that include rehabilitation"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: intracerebral stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "intracerebral stem cell transplantation",
                              "conventional treatment"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01714167"
                        ]
                  },
                  {
                        "Rank": 79,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 \u00d7 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.",
                              "1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived MSCs",
                              "Drug: Compound betamethasone"
                        ],
                        "ArmGroupLabel": [
                              "Autologous adipose-derived MSCs",
                              "Compound betamethasone"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03279796"
                        ]
                  },
                  {
                        "Rank": 80,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of cultured autologous bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous BMSCs",
                              "Drug: bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous BMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02327832"
                        ]
                  },
                  {
                        "Rank": 81,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01274975"
                        ]
                  },
                  {
                        "Rank": 82,
                        "Acronym": [
                              "MESCAMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.",
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells",
                              "Suspension media"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02239393"
                        ]
                  },
                  {
                        "Rank": 83,
                        "Acronym": [
                              "ARTROCELL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with 40 millions of autologous autologous adult mesenchymal stem cells from expanded bone marrow administered intra-articularly.",
                              "Treatment with 40 millions of adult allogeneic expanded bone marrow mesenchymal stem cells administered intra-articularly.",
                              "Hyaluronic Acid 60mg/3ml administered intra-articularly."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous MSCs",
                              "Drug: Allogenic MSCs",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stromal Cells (MSC)",
                              "Allogenic Mesenchymal Stromal Cells (MSC)",
                              "Active Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05086939"
                        ]
                  },
                  {
                        "Rank": 84,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10^8 total HB-adMSC cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04228666"
                        ]
                  },
                  {
                        "Rank": 85,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01300598"
                        ]
                  },
                  {
                        "Rank": 86,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three intra-articular injections in total and autologous adipose-derived mesenchymal stem cells (AMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.",
                              "Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Auotologous AMSCs plus autologous PRP",
                              "Biological: Auotologous PRP"
                        ],
                        "ArmGroupLabel": [
                              "AMSCs plus PRP group",
                              "PRP group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04212728"
                        ]
                  },
                  {
                        "Rank": 87,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of freshly collected autologous adipose tissue"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Injection of autologous adipose tissue in anal fistula"
                        ],
                        "ArmGroupLabel": [
                              "Injection with adipose tissue"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04834609"
                        ]
                  },
                  {
                        "Rank": 88,
                        "Acronym": [
                              "UwmBmmscALS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Biological: Cell-based therapy of autologous bone marrow-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Biological: Cell-based therapy"
                        ],
                        "ArmGroupLabel": [
                              "Autologous BM-MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02881489"
                        ]
                  },
                  {
                        "Rank": 89,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: autologous bone marrow derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01306513"
                        ]
                  },
                  {
                        "Rank": 90,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02344849"
                        ]
                  },
                  {
                        "Rank": 91,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose Tissue Derived MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue derived MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02474342"
                        ]
                  },
                  {
                        "Rank": 92,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF"
                        ],
                        "ArmGroupLabel": [
                              "MSC-NTF"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01777646"
                        ]
                  },
                  {
                        "Rank": 93,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous mesenchymal stem cells from the adipose tissue in an unique intralesional infusion with a dose of 40 million cells.",
                              "Ringer lactate solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Infusion of mesenchymal stem cells from adipose tissue",
                              "Other: Infusion of placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Ringer lactate solution"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02292628"
                        ]
                  },
                  {
                        "Rank": 94,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.",
                              "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.",
                              "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells low-dose group",
                              "Biological: Mesenchymal stem cells mid-dose group",
                              "Biological: Mesenchymal stem cells high-dose group"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells low-dose group",
                              "Mesenchymal stem cells mid-dose group",
                              "Mesenchymal stem cells high-dose group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01809769"
                        ]
                  },
                  {
                        "Rank": 95,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00250302"
                        ]
                  },
                  {
                        "Rank": 96,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue",
                              "Standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Surgery",
                              "Other: autologous iliac crest",
                              "Procedure: Surgery"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA and surgery",
                              "Autologous iliac crest and surgery"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02230514"
                        ]
                  },
                  {
                        "Rank": 97,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Instrumented posterolateral arthrodesis"
                        ],
                        "ArmGroupLabel": [
                              "MSC seeded onto a phosphate ceramic"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01513694"
                        ]
                  },
                  {
                        "Rank": 98,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single Treatment Group: Eligible patients will be treated with a Gore Bio-A Fistula Plug that has been coated with autologous mesenchymal stromal cells. This is a drug study, specifically phase 1 study of autologous mesenchymal stromal cells. Single dose of 20 million cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Only 1 arm: treatment with MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "Only 1 arm: treatment with MSC-AFP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03014219"
                        ]
                  },
                  {
                        "Rank": 99,
                        "Acronym": [
                              "BIOMAX"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSV treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSV treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01389661"
                        ]
                  },
                  {
                        "Rank": 100,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Arterial infusion of autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "infusion of autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01840540"
                        ]
                  },
                  {
                        "Rank": 101,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Refractory rheumatoid arthritis patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03333681"
                        ]
                  },
                  {
                        "Rank": 102,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Symptoms and Objective Examination"
                        ],
                        "ArmGroupLabel": [
                              "Symptoms and Objective Examination"
                        ],
                        "ArmGroupType": [
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00955669"
                        ]
                  },
                  {
                        "Rank": 103,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00850187"
                        ]
                  },
                  {
                        "Rank": 104,
                        "Acronym": [
                              "LipAge"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose tissue collection and Transdermal injection of the filler agent, composed of mesenchymal stem cells derived from the autologous adipose tissue, associated with hyaluronic acid.",
                              "Transdermal injection of hyaluronic acid only."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Adipose tissue collection",
                              "Biological: Transdermal injection",
                              "Procedure: Transdermal injection"
                        ],
                        "ArmGroupLabel": [
                              "Test",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02034786"
                        ]
                  },
                  {
                        "Rank": 105,
                        "Acronym": [
                              "AMSC-ALS-001"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Suspension of human autologous MSC 3P in 1.5 ml"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Multipotent MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03828123"
                        ]
                  },
                  {
                        "Rank": 106,
                        "Acronym": [
                              "ISIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Control group without intervention nor placebo",
                              "First dose of stem cells",
                              "Second dose of stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Autologous mesenchymal stem cells",
                              "Genetic: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2",
                              "3"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00875654"
                        ]
                  },
                  {
                        "Rank": 107,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Maximal medical therapy which comprises of optimal pharmacological therapy",
                              "Autologous Bone marrrow-derived mesenchymal stem cells implantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BM-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Maximal medical therapy",
                              "Maximal medical therapy and BM-MSCs"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01720888"
                        ]
                  },
                  {
                        "Rank": 108,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients with ankle joint osteoarthritis"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "stem cell recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01436058"
                        ]
                  },
                  {
                        "Rank": 109,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects who receive a radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC)",
                              "Patients receive standard of care.",
                              "Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at time of first stage of BBF",
                              "Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at first and second stage of BBF",
                              "Subjects will receive placebo at first and second stage of BBF"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)",
                              "Biological: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)",
                              "Biological: Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Single dose AMSC treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula",
                              "No Treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula",
                              "Single dose AMSC treatment at first stage of brachiobasilic arteriovenous fistula",
                              "AMSC treatment at first and second stage of brachiobasilic arteriovenous fistula",
                              "Placebo treatment in brachiobasilic arteriovenous fistula"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02808208"
                        ]
                  },
                  {
                        "Rank": 110,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10^6 MSCs per kg body weight in 3 ml saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Repeated MSCs treatment in ALS patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04821479"
                        ]
                  },
                  {
                        "Rank": 111,
                        "Acronym": [
                              "ORTHO-2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.\n\n20x106 cells per cc in a single administration of 7cc"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cultured autologous Mesenchymal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Cultured autologous Mesenchymal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02065167"
                        ]
                  },
                  {
                        "Rank": 112,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04855955"
                        ]
                  },
                  {
                        "Rank": 113,
                        "Acronym": [
                              "EMMES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.",
                              "Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MC-ALPHA",
                              "Drug: Placebo",
                              "Drug: XCEL-MC-ALPHA",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment A: XCEL-MC-ALPHA/Placebo",
                              "Treatment B: Placebo/XCEL-MC-ALPHA"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02495766"
                        ]
                  },
                  {
                        "Rank": 114,
                        "Acronym": [
                              "ASCROD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with autologous ASC",
                              "Treatment with autologous chondrocytes"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Implantation of autologous cells",
                              "Other: Implantation of autologous cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous ASC implantation",
                              "Autologous Chondrocytes implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01399749"
                        ]
                  },
                  {
                        "Rank": 115,
                        "Acronym": [
                              "Implant_bone"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.",
                              "In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Biocomplex: aBM-MSCs/fibrin glue/collagen fleece",
                              "Procedure: Two-stage surgical implant placement"
                        ],
                        "ArmGroupLabel": [
                              "Group-A",
                              "Control Group-B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03070275"
                        ]
                  },
                  {
                        "Rank": 116,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Intravitreal transplantation of mesenchymal stem cell",
                              "Biological: Culture and isolation of autologous bone-marrow mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC transplantion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02330978"
                        ]
                  },
                  {
                        "Rank": 117,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.",
                              "Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Auotologous BMSCs plus autologous PRP",
                              "Biological: Auotologous PRP"
                        ],
                        "ArmGroupLabel": [
                              "BMSCs plus PRP group",
                              "PRP group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03969680"
                        ]
                  },
                  {
                        "Rank": 118,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.",
                              "This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose",
                              "Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose"
                        ],
                        "ArmGroupLabel": [
                              "Lower Dose MSC",
                              "Higher Dose MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03840343"
                        ]
                  },
                  {
                        "Rank": 119,
                        "Acronym": [
                              "PerioRegen"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue",
                              "in Group B (Fibrin glue/collagen fleece), a collagen fleece enriched with autologous fibrin glue devoid of stem cells will fill the osseous defect",
                              "Group C will receive open flap debridement retaining the soft tissue wall of the pocket"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MSCs/fibrin glue/collagen fleece",
                              "Other: Fibrin glue/collagen fleece",
                              "Procedure: Open flap debridement"
                        ],
                        "ArmGroupLabel": [
                              "Group A",
                              "Group B",
                              "Group C"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02449005"
                        ]
                  },
                  {
                        "Rank": 120,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET",
                              "standard endometrial preparation for frozen/thawed ET"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow-derived MSC and HRT",
                              "Other: hormonal replacement therapy"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow-derived MSC and HRT",
                              "hormonal replacement therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03166189"
                        ]
                  },
                  {
                        "Rank": 121,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient will receive a combination of mesenchymal and Hematopoetic stem cell through hepatic artery under fluroscopic guidance",
                              "Diuretics, Hepatoprotective agents and Lactulose"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: CD 34 and MSC infusion",
                              "Drug: Standard of care for Cirrhosis management"
                        ],
                        "ArmGroupLabel": [
                              "Combination MSC and HSC",
                              "Standard of care for Cirrhosis management"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04243681"
                        ]
                  },
                  {
                        "Rank": 122,
                        "Acronym": [
                              "CSM/ON/2011"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.\n\nThey employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.\n\nPharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: bone marrow aspirate"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01700920"
                        ]
                  },
                  {
                        "Rank": 123,
                        "Acronym": [
                              "CME-LEM1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01909154"
                        ]
                  },
                  {
                        "Rank": 124,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: BCP with autologous mesenchymal stem cells (MSC)."
                        ],
                        "ArmGroupLabel": [
                              "Augmentation of new alveolar bone"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02751125"
                        ]
                  },
                  {
                        "Rank": 125,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Expanded autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: expanded autologous bone marrow derived MSC"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04815213"
                        ]
                  },
                  {
                        "Rank": 126,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with CKD who underwent intravenous injection of MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "MSC recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02195323"
                        ]
                  },
                  {
                        "Rank": 127,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture.\n\nMSC will be injected even if the number of available cells is lower than 40 X 10E6.\n\nThe injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist.",
                              "Culture medium used to resuspend the Mesenchymal Stem Cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Other: Culture medium without MSC."
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells",
                              "Culture medium without MSC."
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01429012"
                        ]
                  },
                  {
                        "Rank": 128,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each patient will receive surgery to implant the cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells and all follow-up procedures."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "Tracheal Replacement"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02949414"
                        ]
                  },
                  {
                        "Rank": 129,
                        "Acronym": [
                              "ORTHOUNION"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Cultured Mesenchymal Stem Cells +Biomaterial (Low Dose): 100x106 cells",
                              "Autologous Cultured Mesenchymal Stem Cells+Biomaterial (High Dose): 200x106 cells",
                              "Autologous Iliac Crest Grafting"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cultured Mesenchymal Stem Cells",
                              "Biological: Cultured Mesenchymal Stem Cells",
                              "Procedure: Autologous iliac crest graft"
                        ],
                        "ArmGroupLabel": [
                              "hBM-MSCs-Low Dose",
                              "hBM-MSCs-High Dose",
                              "Autologous iliac crest graft"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03325504"
                        ]
                  },
                  {
                        "Rank": 130,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "posterior cervical laminectomy and Mesenchymal stem cells tranplantation. After laminectomy, 1.6X10^7 and 3.2 X10^7 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: cellgram-spine"
                        ],
                        "ArmGroupLabel": [
                              "cellgram-spine"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01676441"
                        ]
                  },
                  {
                        "Rank": 131,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive six autologous stem cell injections through spinal taps every 2 months over a year.",
                              "Patients will receive six placebo injections through spinal taps every 2 months over a year."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intrathecal MSC-NP injection",
                              "Other: Intrathecal saline injection"
                        ],
                        "ArmGroupLabel": [
                              "Intrathecal MSC-NP injection",
                              "Intrathecal saline injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03355365"
                        ]
                  },
                  {
                        "Rank": 132,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived mesenchymal stem cells",
                              "Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived limbal stem cells",
                              "Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Other: standard treatment",
                              "Biological: limbal stem cells",
                              "Other: standard treatment",
                              "Other: standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "limbal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04484402"
                        ]
                  },
                  {
                        "Rank": 133,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Adipose Tissue derived MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue derived MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01769872"
                        ]
                  },
                  {
                        "Rank": 134,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Isolation and \"Ex-Vivo\" expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-Divisi\u00f3n de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous MSC knee implantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSC knee implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01227694"
                        ]
                  },
                  {
                        "Rank": 135,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Administration of autologous adipose derived SVF"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: AD-SVF"
                        ],
                        "ArmGroupLabel": [
                              "Deployment of AD-SVF"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04064879"
                        ]
                  },
                  {
                        "Rank": 136,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04064957"
                        ]
                  },
                  {
                        "Rank": 137,
                        "Acronym": [
                              "ASCAT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02064062"
                        ]
                  },
                  {
                        "Rank": 138,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.",
                              "Patients were treated with routine drug therapy\uff0cdo not inject stem cell to the facial nerve of patient"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose stem cell therapy",
                              "Drug: Mecobalamin",
                              "Drug: Mecobalamin"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell therapy group",
                              "Neurotrophic drugs treatment group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02853942"
                        ]
                  },
                  {
                        "Rank": 139,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conserved Therapy",
                              "Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Conserved Therapy",
                              "Procedure: Hepatic artery infusion"
                        ],
                        "ArmGroupLabel": [
                              "Conserved Therapy",
                              "Interventional Therapy"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00976287"
                        ]
                  },
                  {
                        "Rank": 140,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow mesenchymal stem cells 10 cc by intra articular injection once",
                              "Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once",
                              "Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow mesenchymal stem cells",
                              "Biological: Adipose Mesenchymal stem cells",
                              "Biological: bone marrow & adipose mesenchymal stem cells injection"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow mesenchymal stem cell",
                              "adipose mesenchymal stem cells",
                              "Bone marrow and Adipose mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04351932"
                        ]
                  },
                  {
                        "Rank": 141,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell injection"
                        ],
                        "ArmGroupLabel": [
                              "MSC injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01741090"
                        ]
                  },
                  {
                        "Rank": 142,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells",
                              "Autologous bone marrow-derived mononuclear cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mononuclear and mesenchymal stem cells",
                              "Biological: Mononuclear cells"
                        ],
                        "ArmGroupLabel": [
                              "Mononuclear and mesenchymal stem cells",
                              "Mononuclear cells only"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01456819"
                        ]
                  },
                  {
                        "Rank": 143,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous MitoCell Transplantation in Subjects with Idiopathic Parkinson's Disease"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Aadipose-Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Single Arm Study"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05094011"
                        ]
                  },
                  {
                        "Rank": 144,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01446614"
                        ]
                  },
                  {
                        "Rank": 145,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose derived, autologous mesenchymal stem cells (AD-MSCs) at a dose of 15 million or 30 million cells will be administered via intra-arterial delivery with interventional radiology to the inferior mesenteric artery in subjects with medically refractory ulcerative colitis."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose derived, autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04312113"
                        ]
                  },
                  {
                        "Rank": 146,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01068951"
                        ]
                  },
                  {
                        "Rank": 147,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose-Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "ADMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02544802"
                        ]
                  },
                  {
                        "Rank": 148,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous BM MSC"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05080465"
                        ]
                  },
                  {
                        "Rank": 149,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight",
                              "Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight",
                              "Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stromal cells (MSCs)",
                              "Biological: Autologous mesenchymal stromal cells (MSCs)",
                              "Biological: Autologous mesenchymal stromal cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Dose Level 1: Infusion of MSCs",
                              "Dose Level 2: Infusion of MSCs",
                              "Dose Level 3: Infusion of MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02359929"
                        ]
                  },
                  {
                        "Rank": 150,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection",
                              "Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Single Injection",
                              "Two Injections"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03608579"
                        ]
                  },
                  {
                        "Rank": 151,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01446640"
                        ]
                  },
                  {
                        "Rank": 152,
                        "Acronym": [
                              "AdMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Phase 2 Arm 1 - OA Knee",
                              "Phase 2 Arm 2 OA Knee",
                              "Phase 2 Arm 3 - OA Hip",
                              "Phase 2 Arm 4 - OA Hip",
                              "Phase 2 Arm 5 - OA Shoulder",
                              "Phase 2 Arm 6 - OA Shoulder"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04448106"
                        ]
                  },
                  {
                        "Rank": 153,
                        "Acronym": [
                              "CELLTOP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive a single dose of 100 million autologous, adipose derived mesenchymal stem cells. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous, Adipose derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Phase I"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03308565"
                        ]
                  },
                  {
                        "Rank": 154,
                        "Acronym": [
                              "DREAM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Two procedures:\n\nBone marrow harvesting from the posterior superior iliac crest region\nSingle injections of a dose of 15 million of autologous BM-MSC for each disc affected by IDD (up to 3 discs) via imaging control",
                              "Two sham procedures:\n\nSimulated bone marrow harvesting without insertion into the posterior iliac crest region\nSimulated injection under only local anaesthesia without disc injection and without placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous BM-MSC",
                              "Procedure: Sham"
                        ],
                        "ArmGroupLabel": [
                              "Active Arm",
                              "Sham Procedure"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05066334"
                        ]
                  },
                  {
                        "Rank": 155,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous MSCs transplantation were performed plus medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin)",
                              "only medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin) were performed without autologous MSCs transplantation."
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "group A",
                              "group B"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00956891"
                        ]
                  },
                  {
                        "Rank": 156,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia",
                              "2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem/stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose-derived mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03876197"
                        ]
                  },
                  {
                        "Rank": 157,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One time infusion of islets plus BM-MSCs at 20x10^6/patient, n=14",
                              "One time infusion of islets plus BM-MSCs at 50x10^6/patient, n=14",
                              "One time infusion of islets only."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow-derived mesenchymal stem cells",
                              "Biological: Bone marrow-derived mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSCs at 20x10^6",
                              "BM-MSCs at 50x10^6",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05095532"
                        ]
                  },
                  {
                        "Rank": 158,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "standard treatment according to clinical protocols plus mesenchymal stem cells",
                              "standard treatment according to clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Other: standard treatment",
                              "Other: standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04434794"
                        ]
                  },
                  {
                        "Rank": 159,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 single arm: Local injection of autologus MSC product (KI-MSC-PL-204) into scarred vocal fold (0,5-1 million cellls/Vocal fold, maximum 2 million cells if bilateral vocal fold scar)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC-KI-PL-204"
                        ],
                        "ArmGroupLabel": [
                              "Single arm: MSC administration to vocal fold scar"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04290182"
                        ]
                  },
                  {
                        "Rank": 160,
                        "Acronym": [
                              "2ABC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous ADSC injection combined with laser therapy of the skin.",
                              "Normal sline injection combined with laser therapy of the skin."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Laser therapy",
                              "Biological: Autologous ADSC injection",
                              "Procedure: Laser therapy",
                              "Procedure: Normal saline injection"
                        ],
                        "ArmGroupLabel": [
                              "Autologous adipose derived stem cells",
                              "Placebo - Normal saline injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03887208"
                        ]
                  },
                  {
                        "Rank": 161,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.\n\n2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02012153"
                        ]
                  },
                  {
                        "Rank": 162,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Thirty of the enrolled patients were randomly assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.",
                              "Thirty of the enrolled patients were randomly assigned to Group B were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as Bone Mesenchymal Stem Cells(BMSC) transplantation via portal vein."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conserved therapy",
                              "Procedure: Autologous BMSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Group A(conserved therapy )",
                              "Group B (BMSC Transplantion)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00993941"
                        ]
                  },
                  {
                        "Rank": 163,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells group refers to treatment with mesenchymal stem cells (1\u00d710^6 cells/kg, intravenously)",
                              "Mesenchymal stem cells and cord blood group refers to treatment with mesenchymal stem cells (at a dose of 1\u00d710^6 cells/kg) and cord blood"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells and cord blood"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Mesenchymal stem cells and cord blood"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01763099"
                        ]
                  },
                  {
                        "Rank": 164,
                        "Acronym": [
                              "TAC-HFT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Participants will receive an injection of 100 million or 200 million autologous human mesenchymal stem cells (hMSCs).",
                              "Participants will receive an injection of 100 million or 200 million autologous human bone marrow cells (hBMCs).",
                              "Participants will receive a placebo injection of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous human mesenchymal cells (hMSCs)",
                              "Biological: Autologous human bone marrow cells (hBMCs)",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2",
                              "3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00768066"
                        ]
                  },
                  {
                        "Rank": 165,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04029896"
                        ]
                  },
                  {
                        "Rank": 166,
                        "Acronym": [
                              "CMM/FPI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Endobronchial infusion of adult mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells derived from bone marrow"
                        ],
                        "ArmGroupLabel": [
                              "MSC endobronchial infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01919827"
                        ]
                  },
                  {
                        "Rank": 167,
                        "Acronym": [
                              "MSCIMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: MSC Treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSC Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00395200"
                        ]
                  },
                  {
                        "Rank": 168,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion",
                              "Instrumented spinal fusion together with patient's bone iliac crest."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA",
                              "Standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01552707"
                        ]
                  },
                  {
                        "Rank": 169,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each subject receives three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days\n\nOther Names: Celltex-AdMSCs Celltex-AdMSCs",
                              "The control group- receive three doses of placebo via intravenously infusion every three days."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose-derived stem cells",
                              "Biological: autologous adipose-derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Phase 2 AdMSC group",
                              "Phase 2 Placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04428801"
                        ]
                  },
                  {
                        "Rank": 170,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous MMSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Study group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04146519"
                        ]
                  },
                  {
                        "Rank": 171,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "control arm with sham transplantation",
                              "Active arm with transplantation of cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: sham transplantation of mesenchymal stem cells",
                              "Biological: autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "sham transplantation of mesenchymal stem cells",
                              "autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02057211"
                        ]
                  },
                  {
                        "Rank": 172,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00557635"
                        ]
                  },
                  {
                        "Rank": 173,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly",
                              "One dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Stromal Vascular Fraction (SVF)",
                              "Biological: Autologous Adipose Derieved MSCs",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Stromal Vascular Fraction",
                              "Autologous Adipose Derived MSCs",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02145897"
                        ]
                  },
                  {
                        "Rank": 174,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.\n\nThe treatment will be carried out after the patient has received a blood test and clinically evaluated at T0.\n\nT0: Beginning of the study, blood test and bone marrow aspiration. T30: Intra-articular injection of MSCs T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)",
                              "The patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) The hyaluronic acid will be purchased for the patient from the manufacturer or from the pharmacy of the hospital.The intra-articular injection will be carried out after the patient has received a clinical evaluation at T0.\n\nT0: Beginning of the study T30: Intra-articular injection of Synvisc-One (HA) T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells Treatment (MSCs)",
                              "Drug: Hyaluronic acid (HA)"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells Treatment (MSCs)",
                              "Hyaluronic acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04326985"
                        ]
                  },
                  {
                        "Rank": 175,
                        "Acronym": [
                              "MESAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After bone-marrow aspiration by an authorized person, Mesenchymal Stem Cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of Mesenchymal Stem Cells during Left Ventricular Assist Device surgery"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02460770"
                        ]
                  },
                  {
                        "Rank": 176,
                        "Acronym": [
                              "NurOwn"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration",
                              "Combined intramuscular and intrathecal placebo administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous MSC-NTF cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSC-NTF cells",
                              "Excipient"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02017912"
                        ]
                  },
                  {
                        "Rank": 177,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Bone marrow derived stem cells transplant"
                        ],
                        "ArmGroupLabel": [
                              "Therapy for Parkinson's disease"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00976430"
                        ]
                  },
                  {
                        "Rank": 178,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stem Cell Preparation and Injection:\n\nStem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared and suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .\n\nStem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cell Preparation and Injection"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cell Preparation and Injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02062931"
                        ]
                  },
                  {
                        "Rank": 179,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous mesenchymal stem cell transplantation",
                              "Procedure: Autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "A",
                              "B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00476060"
                        ]
                  },
                  {
                        "Rank": 180,
                        "Acronym": [
                              "TEAM-AMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Atorvastatin routine dose + placebo transplantation",
                              "Atorvastatin routine dose + low dose BMMSC Transplantation",
                              "Atorvastatin routine dose + middle dose BMMSC Transplantation",
                              "Atorvastatin routine dose + high dose BMMSC Transplantation",
                              "Atorvastatin routine dose + placebo transplantation",
                              "Atorvastatin routine dose+ Optimal dose BMMSC Transplantation",
                              "Atorvastatin Intensive dose + placebo transplantation",
                              "Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Atorvastatin",
                              "Drug: Atorvastatin",
                              "Drug: Low dose BMMSC",
                              "Drug: Atorvastatin",
                              "Drug: Middle dose BMMSC",
                              "Drug: Atorvastatin",
                              "Drug: High dose BMMSC",
                              "Drug: Atorvastatin",
                              "Drug: Atorvastatin",
                              "Drug: Transplantation",
                              "Drug: Intensive Atorvastatin",
                              "Drug: Intensive Atorvastatin",
                              "Drug: Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Phase A: Atorvastatin",
                              "Phase A: Low dose BMMSC",
                              "Phase A: Middle dose BMMSC",
                              "Phase A: High dose BMMSC",
                              "Phase B: Atorvastatin",
                              "Phase B: Atorvastatin+Transplantation",
                              "Phase B: Intensive Atorvastatin",
                              "Phase B: Intensive Atorvastatin+Transplantation"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator",
                              "Active Comparator",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03047772"
                        ]
                  },
                  {
                        "Rank": 181,
                        "Acronym": [
                              "MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: two doses of autologous bone marrow (BM) derived Mesenchymal Stromal Cells IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican\u00ae (1.5mg/day). Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight.\n\nAt the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus wil be halved, after 2 weeks stopped)",
                              "Patients in the control group will receive Certican\u00ae (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells + Everolimus",
                              "Everolimus + Tacrolimus"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02057965"
                        ]
                  },
                  {
                        "Rank": 182,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 2 x 106/ml concentrated solution",
                              "High dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 4 x 106/ml concentrated solution",
                              "Comparative analysis of psychometric and morphometric based data"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC Treatment group 1 (low dose)",
                              "Drug: MSC Treatment group 2 (high dose)",
                              "Other: Healthy Control (no treatment)"
                        ],
                        "ArmGroupLabel": [
                              "MSC treatment group 1",
                              "MSC treatment group 2",
                              "Healthy Control (no treatment)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03692221"
                        ]
                  },
                  {
                        "Rank": 183,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in Group A will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive standard regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF.",
                              "Patients in Group B will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive 80% less of calcineurin inhibitor than in Group A. Other immunosuppressive agents such as glucocorticoid and MMF remained the same doses as in Group A.",
                              "Patients in Group C will receive anti-interleukin 2 receptor antibody (Basiliximab)for induction therapy. Patients will receive the same doses of regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF as in Group A."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Kidney transplantation with MSCs infusion",
                              "Procedure: Kidney transplantation with MSCs infusion",
                              "Procedure: kidney transplantation without MSC infusion"
                        ],
                        "ArmGroupLabel": [
                              "A",
                              "B",
                              "C"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00658073"
                        ]
                  },
                  {
                        "Rank": 184,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A group treated with a stromal vascular fraction (SVF) with mesenchymal stromal cells (MSC) injection in the knee joint after an enzymatic digestion of autologous adipose tissue",
                              "A group treated with a mechanically fragmented (using Lipogems device) autologous adipose tissue injection in the knee joint"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint",
                              "Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint"
                        ],
                        "ArmGroupLabel": [
                              "Enzymatic digestion group",
                              "Mechanical fragmentation group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04675359"
                        ]
                  },
                  {
                        "Rank": 185,
                        "Acronym": [
                              "STARTING-2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treatment",
                              "Standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01716481"
                        ]
                  },
                  {
                        "Rank": 186,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01142856"
                        ]
                  },
                  {
                        "Rank": 187,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Long-term follow up of Mesenchymal stem cell group"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: no Intervention"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03933995"
                        ]
                  },
                  {
                        "Rank": 188,
                        "Acronym": [
                              "AMSC-RC-001"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive perioperative hAMSC (1.5 ml) treatment in order to accelerate the healing of the surgically repaired rotator cuff and increase the mechanical properties of the tendon."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Suspension of human autologous MSC 3P"
                        ],
                        "ArmGroupLabel": [
                              "Suspension of human autologous MSC 3P"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03838666"
                        ]
                  },
                  {
                        "Rank": 189,
                        "Acronym": [
                              "AMSC-DSD-001"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Suspension of human autologous MSC 3P in 1.5 ml"
                        ],
                        "ArmGroupLabel": [
                              "Human AMSC (passage 3) 3P in 1.5 mL"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03827096"
                        ]
                  },
                  {
                        "Rank": 190,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)",
                              "only has intracytoplasmic sperm injection (ICSI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: autologous mitochondria transplantation",
                              "Combination Product: autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)",
                              "Drug: intracytoplasmic sperm injection (ICSI)"
                        ],
                        "ArmGroupLabel": [
                              "autologous mitochondria transplantation",
                              "ICSI"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03639506"
                        ]
                  },
                  {
                        "Rank": 191,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.",
                              "The patients with nonunion fracture who underwent percutaneous injection of placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Percutaneous injection",
                              "Other: Percutaneous injection"
                        ],
                        "ArmGroupLabel": [
                              "MSC recipients",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02448849"
                        ]
                  },
                  {
                        "Rank": 192,
                        "Acronym": [
                              "Maxibone"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The gold standard; Bone block from the ramus of the nation will be transplanted to the alveolar ridge.",
                              "Expanded, autologous mesenchymal stem cells in combination with biphasic calcium phosphate"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous bone graft",
                              "Combination Product: Advanced medicinal Therapy (MSC combined with biomaterial)"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Test"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04297813"
                        ]
                  },
                  {
                        "Rank": 193,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Administrated for intra-articular use of Mesenchymal progenitor cells",
                              "Administrated for intra-articular use of Sodium Hyaluronate."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal progenitor cells",
                              "Biological: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal progenitor cells",
                              "Sodium Hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02162693"
                        ]
                  },
                  {
                        "Rank": 194,
                        "Acronym": [
                              "S-CURE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in CSWT+BMMSCs group will receive a 3-month cardiac shock wave therapy and then a total of 1 million/kg BMMSCs will be infused using the stop-flow technique through an over-the-wire balloon catheter positioned in a coronary artery or bypass graft supplying the targeting viable myocardium.",
                              "Placebo group will receive a 3-month CSWT and a sham procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: CSWT+BMMSCs",
                              "Device: CSWT+Sham operation"
                        ],
                        "ArmGroupLabel": [
                              "CSWT+BMMSCs",
                              "CSWT+Sham operation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03397095"
                        ]
                  },
                  {
                        "Rank": 195,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03069209"
                        ]
                  },
                  {
                        "Rank": 196,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.",
                              "The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Osteoarthritis",
                              "Cartilage"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03477942"
                        ]
                  },
                  {
                        "Rank": 197,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of autologous bone marrow-derived mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous bone marrow-derived mesenchymal stem cells."
                        ],
                        "ArmGroupLabel": [
                              "Safety"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01162915"
                        ]
                  },
                  {
                        "Rank": 198,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Five IV infusions of autologous, adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety lab follow ups at weeks 6, 14, 26; inflammatory marker follow ups at weeks 6, 14, 26; SF-36 and PHQ-9 Questionnaires at weeks 2,6,10, 14, 18, 22, 26."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04349631"
                        ]
                  },
                  {
                        "Rank": 199,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with ultra filtration failure (UFF) underwent AD-MSC injection.",
                              "The patients with ultra filtration failure (UFF) underwent Placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection",
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02801890"
                        ]
                  },
                  {
                        "Rank": 200,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.",
                              "Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.",
                              "Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.",
                              "Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: 50 Adipose Derived Stem Cell Infusion",
                              "Drug: 150 Adipose Derived Stem Cell Infusion",
                              "Drug: 300 Adipose Derived Stem Cell Infusion",
                              "Drug: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "50 million cell infusion",
                              "150 million cell infusion",
                              "300 million cell infusion",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04744051"
                        ]
                  },
                  {
                        "Rank": 201,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NurOwn (MSC-NTF cells)"
                        ],
                        "ArmGroupLabel": [
                              "NurOwn (MSC-NTF cells)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03799718"
                        ]
                  },
                  {
                        "Rank": 202,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous MSC, 5\u00d710^7 cells, one injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: RegStem"
                        ],
                        "ArmGroupLabel": [
                              "RegStem"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03007576"
                        ]
                  },
                  {
                        "Rank": 203,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous BM MSC"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03626090"
                        ]
                  },
                  {
                        "Rank": 204,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03822858"
                        ]
                  },
                  {
                        "Rank": 205,
                        "Acronym": [
                              "ACTIVE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Two interventions:\n\nBone marrow harvesting from the posterior superior iliac crest region\nSingle injections of a dose of 15 million of autologous BM-MSC each disc affected by IDD (up to 4 discs) via imaging control",
                              "Two sham procedures:\n\nSimulated bone marrow harvesting without insertion into the posterior iliac crest region\nSimulated injection under only local anaesthesia without disc injection, without placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous BM-MSC",
                              "Other: Sham Procedure"
                        ],
                        "ArmGroupLabel": [
                              "Autologous BM-MSC injection",
                              "Sham Procedure"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04759105"
                        ]
                  },
                  {
                        "Rank": 206,
                        "Acronym": [
                              "ADIPOA-2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.",
                              "Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.",
                              "0.5% glucose in saline with 4.5% albumin"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection (2x106 ASC/5ml).",
                              "Biological: Injection (10x106 ASC/5ml).",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "2x106 ASC intra-articular injection",
                              "10x106 ASC intra-articular injection",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02838069"
                        ]
                  },
                  {
                        "Rank": 207,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HB-adMSCs will be infused three times over a six week period, spaced 14 days apart"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04063215"
                        ]
                  },
                  {
                        "Rank": 208,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cell Autologous MSC transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "2"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00659217"
                        ]
                  },
                  {
                        "Rank": 209,
                        "Acronym": [
                              "ADASCs-CT-CD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "5 patients, who will receive adipose tissue mesenchymal stem cells in a single dose as study treatment",
                              "5 patients, who will receive decellularized corneal laminas as treatment medication",
                              "5 patients, who will receive adipose tissue mesenchymal cells combined with decellularized corneal laminas as study treatment in a single intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Implantation",
                              "Procedure: Lipoaspiration",
                              "Procedure: Implantation",
                              "Procedure: Implantation",
                              "Procedure: Lipoaspiration"
                        ],
                        "ArmGroupLabel": [
                              "ADASCs Group",
                              "Acellular laminas group",
                              "ADASCs recellularized laminas group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05279157"
                        ]
                  },
                  {
                        "Rank": 210,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients received treatment of a stem cell coated fistula plug."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC Fistula Plug"
                        ],
                        "ArmGroupLabel": [
                              "MSC Fistula plug: Single Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02807389"
                        ]
                  },
                  {
                        "Rank": 211,
                        "Acronym": [
                              "HB-adMSCs"
                        ],
                        "AgreementOtherDetails": [
                              "In the protocol signature page, the investigator agreed to the following: \"I further agree to treat the results of this Study as confidential information and will not submit the results of the Study for publication without prior written authorization from Hope Biosciences. \""
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03691909"
                        ]
                  },
                  {
                        "Rank": 212,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)",
                              "No treatment (after high tibial osteotomy)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue derived MSCs",
                              "No treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03000712"
                        ]
                  },
                  {
                        "Rank": 213,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in the test group received autologous peripheral blood mesenchymal stem cell therapy",
                              "Patients in the control group 1 received microfracture surgical treatment",
                              "Patients in the control group 2 received microfracture combined with surgical treatment of collagen membrane",
                              "Patients in the control group 3 received autologous osteochondral transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: autologous peripheral blood mesenchymal stem cell",
                              "Procedure: Microfracture",
                              "Combination Product: Microfracture + collagen membrane",
                              "Procedure: Autologous osteochondral transplantation"
                        ],
                        "ArmGroupLabel": [
                              "test group",
                              "control group 1",
                              "control group 2",
                              "control group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04953572"
                        ]
                  },
                  {
                        "Rank": 214,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 x 10^6 MSCs",
                              "10 x 10^6 MSCs",
                              "50 x 10^6 MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: 1 x 10^6 MSCs",
                              "Biological: 10 x 10^6 MSCs",
                              "Biological: 50 x 10^6 MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02351011"
                        ]
                  },
                  {
                        "Rank": 215,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Best Supportive care",
                              "Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.",
                              "Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Livercellgram",
                              "Biological: Livercellgram"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "1-time injection group: Livercellgram",
                              "2-time injection group: Livercellgram"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01875081"
                        ]
                  },
                  {
                        "Rank": 216,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single Treatment Group"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02589119"
                        ]
                  },
                  {
                        "Rank": 217,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional standard therapy and control saline spray",
                              "Conventional standard therapy and fibrin spray",
                              "Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Stem Cell",
                              "Genetic: Stem Cell",
                              "Genetic: Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Standard therapy and control saline spray",
                              "standard therapy and fibrin spray",
                              "Conventional standard therapy and MSCs"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Sham Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01751282"
                        ]
                  },
                  {
                        "Rank": 218,
                        "Acronym": [
                              "Bmmsct"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Receive the best medication, percutaneous coronary intervention, and bone marrow mesenchymal stem cells transfer(Intracoronary artery )",
                              "Receive the best medication, percutaneous coronary intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow mesenchymal stem cells transfer",
                              "Drug: Best medical treatment",
                              "Procedure: Percutaneous coronary intervention",
                              "Drug: Best medical treatment",
                              "Procedure: Percutaneous coronary intervention"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04421274"
                        ]
                  },
                  {
                        "Rank": 219,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eligible patients will be treated, single treatment group, no placebo arm."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP Single Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03220243"
                        ]
                  },
                  {
                        "Rank": 220,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: HYNR-CS inj.\n\nTreatment group with HYNR-CS inj."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HYNR-CS inj."
                        ],
                        "ArmGroupLabel": [
                              "Single arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02210624"
                        ]
                  },
                  {
                        "Rank": 221,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.",
                              "The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.",
                              "The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)",
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)",
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)"
                        ],
                        "ArmGroupLabel": [
                              "5 million MSC",
                              "10 million MSC",
                              "15 million MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02603744"
                        ]
                  },
                  {
                        "Rank": 222,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "xerostomy using mesenchymal stem cells adult autologous bone marrow"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "treatment with mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03743155"
                        ]
                  },
                  {
                        "Rank": 223,
                        "Acronym": [
                              "TAC-HFT-II"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.",
                              "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.",
                              "Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous hMSCs",
                              "Device: Biosense Webster MyoStar NOGA Injection Catheter System",
                              "Drug: Autologous Human C-Kit CSCs II",
                              "Device: Biosense Webster MyoStar NOGA Injection Catheter System",
                              "Drug: Placebo",
                              "Device: Biosense Webster MyoStar NOGA Injection Catheter System"
                        ],
                        "ArmGroupLabel": [
                              "Group A - Autologous hMSCs",
                              "Group B - Autologous Human C-Kit CSCs II",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02503280"
                        ]
                  },
                  {
                        "Rank": 224,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)",
                              "Normal Saline with Autologous Serum"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: JointStem",
                              "Other: Placebo Control"
                        ],
                        "ArmGroupLabel": [
                              "JointStem",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04368806"
                        ]
                  },
                  {
                        "Rank": 225,
                        "Acronym": [
                              "MSCSHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients",
                              "Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: adipose-derived mesenchymal stem cells",
                              "Combination Product: adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell Administration for female patients",
                              "Stem cell Administration for male patients"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03346967"
                        ]
                  },
                  {
                        "Rank": 226,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients in this group will be treated by the ACIC technique, which uses autologous collagen to regenerate articular cartilage. ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.",
                              "The patients in this group will be treated by the MCIC technique, which uses concentrated BMAC to regenerate articular cartilage. MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: ACIC",
                              "Device: implant with a collagen + fibrin gel mixture",
                              "Procedure: MCIC"
                        ],
                        "ArmGroupLabel": [
                              "ACIC",
                              "MCIC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01984450"
                        ]
                  },
                  {
                        "Rank": 227,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous injection of mesenchymal stem cell in patients with PKD"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02166489"
                        ]
                  },
                  {
                        "Rank": 228,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program",
                              "Standard rehabilitation program"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-M-ALPHA and standard rehabilitation",
                              "Other: Rehabilitation"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-M-ALPHA and standard rehabilitation",
                              "standard rehabilitation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02033525"
                        ]
                  },
                  {
                        "Rank": 229,
                        "Acronym": [
                              "MSC-pMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with intrathecal and intravenous injection of autologous MSC (1 million cells per Kg of body weight)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Repeated MSCs treatment in MS patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04823000"
                        ]
                  },
                  {
                        "Rank": 230,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cells only"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "stem cells group"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02705742"
                        ]
                  },
                  {
                        "Rank": 231,
                        "Acronym": [
                              "MSC-AFP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Only 1 arm: treatment with MSC-AFP"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01915927"
                        ]
                  },
                  {
                        "Rank": 232,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three Intrathecal administrations of NurOwn\u00ae (MSC-NTF cells) at bi-monthly intervals",
                              "Three Intrathecal administrations of Placebo at bi-monthly intervals"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NurOwn\u00ae (MSC-NTF cells)",
                              "Other: Bone Marrow aspiration",
                              "Other: Placebo",
                              "Other: Bone Marrow aspiration"
                        ],
                        "ArmGroupLabel": [
                              "NurOwn\u00ae (MSC-NTF cells)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03280056"
                        ]
                  },
                  {
                        "Rank": 233,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head",
                              "Isolated core decompression"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA",
                              "Standard Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01605383"
                        ]
                  },
                  {
                        "Rank": 234,
                        "Acronym": [
                              "CONCERT-HF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Target dose of 150 million MSCs",
                              "Target dose of 5 million c-kit+ cells",
                              "Target dose of 150 million MSCs and 5 million c-kit+ cells",
                              "Plasmalyte A"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSC)",
                              "Biological: c-kit+ cells",
                              "Biological: Mesenchymal Stem Cells (MSC)",
                              "Biological: c-kit+ cells",
                              "Biological: Placebo (Plasmalyte A)"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells (MSC)",
                              "c-kit+ cells",
                              "Combination Cells (MSC and c-kit+ cells)",
                              "Placebo (Plasmalyte A)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004"
                        ],
                        "NCTId": [
                              "NCT02501811"
                        ]
                  },
                  {
                        "Rank": 235,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells",
                              "Patients treated according to current clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Olfactory mucosa-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treated group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03130374"
                        ]
                  },
                  {
                        "Rank": 236,
                        "Acronym": [
                              "ACellDREAM2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients administrated with autologous ASC in their ischemic inferiors limbs"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell)"
                        ],
                        "ArmGroupLabel": [
                              "ASC (Adipose-derived Stem/Stroma Cells)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03968198"
                        ]
                  },
                  {
                        "Rank": 237,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with spinal cord injury that will undergo autologous bone marrow stem cell transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cell Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01325103"
                        ]
                  },
                  {
                        "Rank": 238,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1",
                              "30 subjects receive three doses of 2.0-2.86\u00d710^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a",
                              "15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose derived stem cells",
                              "Biological: autologous adipose derived stem cells",
                              "Biological: autologous adipose derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1 ARM 0",
                              "Phase 2 ARM 1",
                              "Phase 2 ARM 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04170426"
                        ]
                  },
                  {
                        "Rank": 239,
                        "Acronym": [
                              "Cellgram-LC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Best Supportive care",
                              "Within 1 month after extracting bone marrow, directly inject 7X10^7 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cellgram-LC"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Injection group: Cellgram-LC"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04689152"
                        ]
                  },
                  {
                        "Rank": 240,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A bone marrow aspiration will be performed from the iliac crest. The bone marrow aspirate will be processed using a bone marrow aspirate concentrate (BMAC) harvesting system. The osteochondral allograft plug will then be soaked in the BMAC for a minimum 2 minutes prior to implantation. The remaining BMAC will be placed in the defect site prior to plug implantation.",
                              "The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed. The osteochondral allograft plug will not be soaked in BMAC prior to implantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation",
                              "Procedure: Control group incision"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow Aspiration Group",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04739930"
                        ]
                  },
                  {
                        "Rank": 241,
                        "Acronym": [
                              "Lipo-Hip"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will be treated with an intra-articular-ultrasound-guided injection of Micro-fragmented adipose tissue containing mesenchymal stromal cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Micro-fragmented adipose tissue injection"
                        ],
                        "ArmGroupLabel": [
                              "MF-AT injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05465096"
                        ]
                  },
                  {
                        "Rank": 242,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with tracheal/laryngeal stenosis receiving standard surgical treatment and mesenchymal stem cells",
                              "Patients with tracheal/laryngeal stenosis receiving standard surgical treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Olfactory mucosa-derived mesenchymal stem cells",
                              "Other: Patients treated according to current clinical protocols",
                              "Other: Patients treated according to current clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "Patients with tracheal/laryngeal stenosis receiving standard treatment and stem cells",
                              "Patients with tracheal/laryngeal stenosis receiving standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05535803"
                        ]
                  },
                  {
                        "Rank": 243,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01143168"
                        ]
                  },
                  {
                        "Rank": 244,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow-derived stem cell transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03067870"
                        ]
                  },
                  {
                        "Rank": 245,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intervention with transplantation of autologous purified stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cell Transplantation"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02641769"
                        ]
                  },
                  {
                        "Rank": 246,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.",
                              "Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Auto-hMSCs",
                              "Biological: Allo-hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Auto-hMSCs",
                              "Allo-hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01087996"
                        ]
                  },
                  {
                        "Rank": 247,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03449069"
                        ]
                  },
                  {
                        "Rank": 248,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first three subjects (minimum) will receive four weekly infusions of MSCs.",
                              "If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.",
                              "If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous MSCs",
                              "Biological: Autologous MSCs",
                              "Biological: Autologous MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSC dose level 1",
                              "MSC dose level 2",
                              "MSC dose level 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03298399"
                        ]
                  },
                  {
                        "Rank": 249,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01663376"
                        ]
                  },
                  {
                        "Rank": 250,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Jointstem"
                        ],
                        "ArmGroupLabel": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03509025"
                        ]
                  },
                  {
                        "Rank": 251,
                        "Acronym": [
                              "ANTG-ASC-210"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low dose group",
                              "high dose group"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous cultured adipose derived stem cells(low dose group)",
                              "Biological: Autologous cultured adipose derived stem cells(high dose group)"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01314092"
                        ]
                  },
                  {
                        "Rank": 252,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.\n\nParticipants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.",
                              "Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion",
                              "Other: Normal Saline (Placebo) Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Stem Cells Infusion",
                              "Placebo Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03478215"
                        ]
                  },
                  {
                        "Rank": 253,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with nonunion fracture of long bones"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: cell injection"
                        ],
                        "ArmGroupLabel": [
                              "non union"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01206179"
                        ]
                  },
                  {
                        "Rank": 254,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of autologous bone marrow-derived mesenchymal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: MSCs injection"
                        ],
                        "ArmGroupLabel": [
                              "MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01913886"
                        ]
                  },
                  {
                        "Rank": 255,
                        "Acronym": [
                              "MESAMI2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "injection of human albumin 4%",
                              "intramyocardial injection of 6.10e7 stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebo comparator",
                              "Drug: Autologous MSC from bone marrow"
                        ],
                        "ArmGroupLabel": [
                              "Placebo comparator",
                              "Autologous MSC from bone marrow"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02462330"
                        ]
                  },
                  {
                        "Rank": 256,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1: Participants will receive a single intrathecal dose of 1 \u00d7 10(7) mesenchymal stem cells (MSCs)",
                              "Group 2: Participants will receive one intrathecal dose of 5 \u00d7 10(7) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 5 \u00d7 10(7) MSCs approximately one month later",
                              "Group 3: Participants will receive one intrathecal dose of 1 \u00d7 10(8) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 1 \u00d7 10(8) MSCs approximately one month later",
                              "Group 4: Participants will receive up to 10 doses of 5 x 10(7) (\u00b120%) mesenchymal stem cells (MSCs) approximately 6 months apart.",
                              "Group 5: Participants will receive up to 10 doses of 2.5 x 10(7) (\u00b120%) mesenchymal stem cells (MSCs) approximately 6 months apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "1 dose of 1 \u00d7 10(7) MSCs",
                              "2 doses of 5 \u00d7 10(7) MSCs",
                              "2 doses of 1 \u00d7 10(8) MSCs",
                              "10 doses of 5 x 10(7) (\u00b120%) MSCs",
                              "10 doses of 2.5 x 10(7) (\u00b120%) MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02315027"
                        ]
                  },
                  {
                        "Rank": 257,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "(Autologous Adipose-derived Mesenchymal Stem Cells)",
                              "Standard comparator"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ASC",
                              "Drug: Fibringlue"
                        ],
                        "ArmGroupLabel": [
                              "ASC (test arm)",
                              "Fibringlue"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04612465"
                        ]
                  },
                  {
                        "Rank": 258,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived MSCs",
                              "saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM",
                              "Drug: saline"
                        ],
                        "ArmGroupLabel": [
                              "JOINTSTEM",
                              "saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03990805"
                        ]
                  },
                  {
                        "Rank": 259,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.\n\nSubjects with uremia in the intervention group will undergo puncture to collect SVF\nSVF will be cultured to abstain MSC\nThe abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD.",
                              "induction with Basiliximab during kidney transplantation from DCD"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: SVFderived MSC transplantations",
                              "Drug: Basiliximab"
                        ],
                        "ArmGroupLabel": [
                              "SVF(Stromal Vascular Fraction) derived MSC transprlantation",
                              "Basiliximab"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02492490"
                        ]
                  },
                  {
                        "Rank": 260,
                        "Acronym": [
                              "CSM/OP/2011"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Fucosylated MSC for Osteoporosis"
                        ],
                        "ArmGroupLabel": [
                              "Fucosylated MSC for Osteoporosis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02566655"
                        ]
                  },
                  {
                        "Rank": 261,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03925649"
                        ]
                  },
                  {
                        "Rank": 262,
                        "Acronym": [
                              "BMAC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in this group will receive between 1-4 ml of bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells (MSCs) obtained from their iliac crest. A small incision will be made on the anterior superior iliac spine in order to withdraw the aspirate. The aspirate will be ran through a centrifuge in order to isolate the BMAC containing MSCs. The BMAC will be injected into the ACL allograft prior to implanting into the patient.",
                              "Patients will receive a sham incision on the anterior superior iliac spine where the bone marrow aspirate is obtained in the the experimental group. This ensures proper blinding. The patient will receive the normal standard of care."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Autologous Bone Marrow Derived Mesenchymal Stem Cells",
                              "Other: Sham incision"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell Recipient",
                              "Control Sham Incision"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04650568"
                        ]
                  },
                  {
                        "Rank": 263,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Periurethral injection of autologous bone-marrow derived stem cells.",
                              "Tension-free vaginal tape operation: a midurethral sling operation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cells,Mesenchymal",
                              "Procedure: surgery (TVT)"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells,Mesenchymal",
                              "surgery (TVT)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02334878"
                        ]
                  },
                  {
                        "Rank": 264,
                        "Acronym": [
                              "MESHT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02472002"
                        ]
                  },
                  {
                        "Rank": 265,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.",
                              "3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.",
                              "corticosteroids i.e. Prednisolone \u226410mg/day or \u226420 mg every alternate day\nImmunosuppressants like Cyclophosphamide or Azathioprine at a dose of 2mg/kg/day not exceeding 150 mg/day\nAntioxidants like N-acetylcysteine (NAC) at a dose upto 1800 mg/day.\nPirfenidone at dose upto 1200 to 1800 mg/day"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Stromal Vascular Fraction (SVF)",
                              "Biological: Autologous Adipose Derived MSCs (ADMSCs)",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Stromal Vascular Fraction",
                              "Autologous Adipose Derived MSCs",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02135380"
                        ]
                  },
                  {
                        "Rank": 266,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cell injection"
                        ],
                        "ArmGroupLabel": [
                              "Cirrhotic Patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01454336"
                        ]
                  },
                  {
                        "Rank": 267,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 patients with relapsing remitting multiple sclerosis who receive cell free media",
                              "Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: injection of cell free media",
                              "Biological: intravenous injection of mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "cell free media",
                              "mesenchymal stem cell reciepiants"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01377870"
                        ]
                  },
                  {
                        "Rank": 268,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subject will receive the combined product of autologous cartilage cells and allogeneic AMSCs in a fibrin glue carrier."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier"
                        ],
                        "ArmGroupLabel": [
                              "CartiLage Auto/Allo IMplantation for Focal Hip Cartilage Defects"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05553132"
                        ]
                  },
                  {
                        "Rank": 269,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The number of mesenchymal stromal cells reached after two culture expansion passages.",
                              "Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell",
                              "Biological: Saline"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00644410"
                        ]
                  },
                  {
                        "Rank": 270,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 x 10E6 ASC intra-articular injection (5 ml)",
                              "10 x 10E6 ASC intra-articular injection (5 ml)",
                              "50 x 10E6 ASC intra-articular injection (5 ml)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose derived stem cells administrated for intra-articular use",
                              "Biological: Autologous adipose derived stem cells administrated for intra-articular use",
                              "Biological: Autologous adipose derived stem cells administrated for intra-articular use"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2",
                              "Group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01585857"
                        ]
                  },
                  {
                        "Rank": 271,
                        "Acronym": [
                              "HBMS01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose derived Mesenchymal stem cells (Autologous)",
                              "Normal Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05116540"
                        ]
                  },
                  {
                        "Rank": 272,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "IPF patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03187431"
                        ]
                  },
                  {
                        "Rank": 273,
                        "Acronym": [
                              "NEC15"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients affected by avascular necrosis of the Hip classified by Japanese Investigation Committee criteria"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Core decompression procedure"
                        ],
                        "ArmGroupLabel": [
                              "Hip avascular necrosis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04210440"
                        ]
                  },
                  {
                        "Rank": 274,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of MSCs injected into the submandibular glands of patients with radiation-induced xerostomia"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment with MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04489732"
                        ]
                  },
                  {
                        "Rank": 275,
                        "Acronym": [
                              "PoseidonDCM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.",
                              "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous hMSCs",
                              "Biological: Allogeneic hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Autologous hMSCs",
                              "Allogeneic hMSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Class I - no limitation",
                              "Class II - Slight Limitation of Physical Activity",
                              "Class III - Marked Limitation of Physical Activity",
                              "Class IV -Inability to carry on physical activity"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT01392625"
                        ]
                  },
                  {
                        "Rank": 276,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02152657"
                        ]
                  },
                  {
                        "Rank": 277,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group of low dose of Mesenchymal stem cells.",
                              "Group of mid dose of mesenchymal stem cells",
                              "Controlled group with no intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous adipose derived mesenchymal stem cells",
                              "Drug: Autologous adipose derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells 0,5 million * weight (kg)",
                              "Mesenchymal stem cells 1 million * weight (kg)",
                              "Controlled group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01257776"
                        ]
                  },
                  {
                        "Rank": 278,
                        "Acronym": [
                              "ENTRUST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will have a patch of expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold surgically implanted to repair bronchial fistula."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BPF-001"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04435249"
                        ]
                  },
                  {
                        "Rank": 279,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells derived from bone marrow infusion",
                              "saline injections"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Biological: saline"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Bone Marrow Stem Cell",
                              "saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02796079"
                        ]
                  },
                  {
                        "Rank": 280,
                        "Acronym": [
                              "RESCeCUF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)",
                              "9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)",
                              "12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Mesenchymal Stem Cell injection",
                              "Procedure: Mesenchymal Stem Cell injection",
                              "Procedure: Mesenchymal Stem Cell injection"
                        ],
                        "ArmGroupLabel": [
                              "Stromal Vascular fraction",
                              "Autologous mesenchymal stem cells",
                              "Allogenic mesenchymal stem cells"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03726255"
                        ]
                  },
                  {
                        "Rank": 281,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will undergo a bone marrow aspirate procedure. Participants will receive a single intra-articular injection of NGRM-001 on treatment day.",
                              "Participants will undergo a bone marrow aspirate procedure. Participants will receive a single subchondral injection of NGRM-001 on treatment day.",
                              "Participants will undergo a bone marrow aspirate procedure. Participants will receive a single combined intra-articular and subchondral injection of NGRM-001 on treatment day.",
                              "Subjects in the corticosteroid group will undergo a mock bone marrow aspirate procedure. Participants will receive a single intra-articular injection of corticosteroid on treatment day."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Derived MSCs",
                              "Device: Bone Marrow Aspirate",
                              "Biological: Bone Marrow Derived MSCs",
                              "Device: Bone Marrow Aspirate",
                              "Biological: Bone Marrow Derived MSCs",
                              "Device: Bone Marrow Aspirate",
                              "Drug: Corticosteroid",
                              "Device: Bone Marrow Aspirate"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs)",
                              "Subchondral injection with Bone Marrow Derived MSCs",
                              "Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCs",
                              "Corticosteroid injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05288725"
                        ]
                  },
                  {
                        "Rank": 282,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Two intrathecal MSC injections"
                        ],
                        "ArmGroupLabel": [
                              "MSC injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02917681"
                        ]
                  },
                  {
                        "Rank": 283,
                        "Acronym": [
                              "msctendonrep"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells with a collagen type I membrane (OrthoADAPT)",
                              "Membrane of collagen type I (OrthoADAPT)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSCs)",
                              "Biological: OrthADAPT"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells (MSCs)",
                              "OrthADAPT"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01687777"
                        ]
                  },
                  {
                        "Rank": 284,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal cells and plasma reach protein are injected to the callus center of short limb"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: cell and RPR injection"
                        ],
                        "ArmGroupLabel": [
                              "cell and RPR recepients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01210950"
                        ]
                  },
                  {
                        "Rank": 285,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01309061"
                        ]
                  },
                  {
                        "Rank": 286,
                        "Acronym": [
                              "MSC-AFP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eligible patients will be treated, single treatment group, no placebo arm"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC-AFP"
                        ],
                        "ArmGroupLabel": [
                              "MSC-AFP Single Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03209700"
                        ]
                  },
                  {
                        "Rank": 287,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00420134"
                        ]
                  },
                  {
                        "Rank": 288,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02749448"
                        ]
                  },
                  {
                        "Rank": 289,
                        "Acronym": [
                              "SEED-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cell",
                              "Drug: Control group"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01392105"
                        ]
                  },
                  {
                        "Rank": 290,
                        "Acronym": [
                              "MILES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants randomized to this arm will undergo bone marrow aspiration and then will be further randomized to receive a standard orthobiologic injection into the knee joint of autologous bone marrow concentrate (BMAC).",
                              "Participants randomized to this arm will undergo small volume lipoplasty, and then will be further randomized to receive an injection into the knee joint of adipose-derived stromal vascular fraction (SVF).",
                              "Participants randomized to this arm will receive an injection into the knee joint of cryopreserved doses of umbilical cord tissue MSCs.",
                              "Participants randomized to the bone marrow derived MSC, adipose-derived MSC, or umbilical cord tissue MSC study arms will be further randomized within the arm in a 3:1 ratio to receive either MSCs derived from the study arm of the initial randomization or a corticosteroid (CS) injection. Participants randomized to the control group will receive an injection of corticosteroid into the knee joint."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Derived MSCs",
                              "Biological: Adipose-derived MSCs",
                              "Biological: Umbilical Cord Tissue (UCT) MSCs",
                              "Drug: Corticosteroid injection"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow Derived MSCs",
                              "Adipose-derived MSCs",
                              "Umbilical Cord Tissue (UCT) MSCs",
                              "Corticosteroid Injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03818737"
                        ]
                  },
                  {
                        "Rank": 291,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hUMAN MESENCHYMAL STEM CELLS"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01877759"
                        ]
                  },
                  {
                        "Rank": 292,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM"
                        ],
                        "ArmGroupLabel": [
                              "JOINTSTEM"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04427930"
                        ]
                  },
                  {
                        "Rank": 293,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will received weekly (n=6) IV infusion of Celyvir."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CELYVIR"
                        ],
                        "ArmGroupLabel": [
                              "CELYVIR"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01844661"
                        ]
                  },
                  {
                        "Rank": 294,
                        "Acronym": [
                              "OrthoCT1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All the patients will have the implantation surgery. This trial is a one-arm study."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Implantation of bone substitute plus autologous cultured mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "Implantation surgery"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01842477"
                        ]
                  },
                  {
                        "Rank": 295,
                        "Acronym": [
                              "MSCPRPOAK"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle",
                              "About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell suspension",
                              "Biological: PRP",
                              "Biological: PRP"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell, PRP",
                              "platelet rich plasma"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01985633"
                        ]
                  },
                  {
                        "Rank": 296,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologue bone marrow mononuclear cell",
                              "Umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC",
                              "Biological: Intravenous Infusion of UC-MSC"
                        ],
                        "ArmGroupLabel": [
                              "BM-MNC experimental",
                              "UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04501341"
                        ]
                  },
                  {
                        "Rank": 297,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01159899"
                        ]
                  },
                  {
                        "Rank": 298,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "infusion of BMMSC+BMMNC and insulin injection",
                              "infusion of BMMNC and insulin injection",
                              "insulin injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: infusion of BMMSCs",
                              "Drug: infusion BMMNCs",
                              "Drug: insulin",
                              "Drug: infusion BMMNCs",
                              "Drug: insulin",
                              "Drug: insulin"
                        ],
                        "ArmGroupLabel": [
                              "BMMSC+BMMNC",
                              "BMMNC",
                              "Insulin"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01719640"
                        ]
                  },
                  {
                        "Rank": 299,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After implementing PCI, contemporary drug treatment is conducted.\n\n*Contemporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotein llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, \u03b2-blocker, CCB, Diuretics, Statin, etc.)",
                              "Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1\u00d710^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Hearticellgram-AMI"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Single dose of Hearticellgram-AMI"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01652209"
                        ]
                  },
                  {
                        "Rank": 300,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: autologous bone marrow derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "autologous bone marrow stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02016508"
                        ]
                  },
                  {
                        "Rank": 301,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04514952"
                        ]
                  },
                  {
                        "Rank": 302,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Peripheral blood stem cell mobilisation and collection",
                              "Drug: High-dose chemotherapy",
                              "Drug: Bone marrow derived allogeneic MMSCs infusion",
                              "Procedure: Autologous peripheral blood stem cells infusion"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic MMSCs infusion"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02145923"
                        ]
                  },
                  {
                        "Rank": 303,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placebo",
                              "a single intravenous autologous bone marrow mononuclear cell transfusion",
                              "a single intravenous autologous marrow stromal cell transfusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: placebo",
                              "Biological: autologous bone marrow mononuclear cell transfusion",
                              "Biological: marrow stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "autologous mononuclear cells",
                              "autologous marrow stromal cells"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00908856"
                        ]
                  },
                  {
                        "Rank": 304,
                        "Acronym": [
                              "HULPURO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose-derived expanded stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose-derived expanded stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous expanded stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01804153"
                        ]
                  },
                  {
                        "Rank": 305,
                        "Acronym": [
                              "StemCell&CKD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants having a harvested total \"Adipose Derived Stem Cell (ADSC)\" count (in 5 ml SVF solution) more than 1 x 10^6.\n\nGenetic: SVF containing Autologous Non Expanded ADSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SVF Containg Autologous Non Expanded ADSC"
                        ],
                        "ArmGroupLabel": [
                              "Group A"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03939741"
                        ]
                  },
                  {
                        "Rank": 306,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose mesenchymal cells with bone marrow mononuclear cells.\n\nTwo doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously.",
                              "Adipose mesenchymal cells with bone marrow mononuclear cells.\n\nTwo doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose mesenchymal cells with bone marrow mononuclear cells",
                              "Biological: Adipose mesenchymal cells with bone marrow mononuclear cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose 1 mil/kg",
                              "Dose 10 mil/kg"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02940418"
                        ]
                  },
                  {
                        "Rank": 307,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04604288"
                        ]
                  },
                  {
                        "Rank": 308,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with ALS that underwent mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: intrathecal injection"
                        ],
                        "ArmGroupLabel": [
                              "stem cell reciepient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01771640"
                        ]
                  },
                  {
                        "Rank": 309,
                        "Acronym": [
                              "STREAMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1-2 x106 MSCs/kg administered at Week 0",
                              "Suspension media administered at Week 0"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01606215"
                        ]
                  },
                  {
                        "Rank": 310,
                        "Acronym": [
                              "Stemshoulder"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All the patients enrolled in the study will be treated with the bone marrow aspirate obtained with the Bone Marrow Cellution Kit."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Marrow Cellution System"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow aspirate"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04308213"
                        ]
                  },
                  {
                        "Rank": 311,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Osteoarthritis A total of 140 patients ( May 2016 to june 2020) were treated with intra articular adipose derived stromal cells (ADSC)) also known as Stromal vascualr fraction administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose tissue derived stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Experimental"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05484856"
                        ]
                  },
                  {
                        "Rank": 312,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC",
                              "Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction",
                              "Other: Standard treatment according to the clinical protocols",
                              "Other: Standard treatment according to the clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC",
                              "Standard treatment according to the clinical protocols"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05520112"
                        ]
                  },
                  {
                        "Rank": 313,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intra spinal injection of 1 \u00d710(8) mesenchymal stem cells +10cc normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02116634"
                        ]
                  },
                  {
                        "Rank": 314,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Oral mucosa biopsy",
                              "Procedure: Sinus lift with implantation of tissue engineered construction",
                              "Device: Dental implant"
                        ],
                        "ArmGroupLabel": [
                              "Tissue engineered construction implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02209311"
                        ]
                  },
                  {
                        "Rank": 315,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Traditional treatment such as insulin,antidiabetes,dressing",
                              "Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG combined with BMMSCs",
                              "Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PRG combined with BMMSCs transplantation",
                              "Biological: PRG combined with BMMSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Traditional treatment",
                              "PRG combined with BMMSCs transplantation",
                              "PRG treatment"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03248466"
                        ]
                  },
                  {
                        "Rank": 316,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: PTA",
                              "Biological: PTA + Infusion of MSC_Apceth"
                        ],
                        "ArmGroupLabel": [
                              "Group B",
                              "Group A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01351610"
                        ]
                  },
                  {
                        "Rank": 317,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "collection of autologous SVF\nculture of SVF to abstain MSC\ninfusion of MSC during and after living-relative kidney transplantation",
                              "The control group will be inducted with Basiliximab"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: SVF-MSC induction",
                              "Drug: Basiliximab induction"
                        ],
                        "ArmGroupLabel": [
                              "SVF-MSC induction",
                              "Basiliximab induction"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02492308"
                        ]
                  },
                  {
                        "Rank": 318,
                        "Acronym": [
                              "PROMETHEUS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells",
                              "Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells",
                              "Participants will receive placebo injections"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Lower dose mesenchymal stem cell (MSC) injection",
                              "Biological: Higher dose MSC injection",
                              "Genetic: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Lower dose mesenchymal stem cell (MSC) injection",
                              "Higher dose MSC injection",
                              "(3) Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00587990"
                        ]
                  },
                  {
                        "Rank": 319,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: JOINTSTEM"
                        ],
                        "ArmGroupLabel": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04825730"
                        ]
                  },
                  {
                        "Rank": 320,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cell Therapy"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03078621"
                        ]
                  },
                  {
                        "Rank": 321,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placenta Derived Mesenchymal Stem Cell administered into the knee joint once",
                              "Sodium hyaluronate administered into the knee joint once"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta Derived Mesenchymal Stem Cell",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Placenta Derived Mesenchymal Stem Cell",
                              "sodium hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03028428"
                        ]
                  },
                  {
                        "Rank": 322,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC and PRP"
                        ],
                        "ArmGroupLabel": [
                              "MSC and PRP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03484741"
                        ]
                  },
                  {
                        "Rank": 323,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In forty cases, the posterolateral fusion was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone allogaft with bone marrow concentrate"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow concentrate"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01603836"
                        ]
                  },
                  {
                        "Rank": 324,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous administration of placebo",
                              "Intravenous administration of 1 million of MSC/ kg",
                              "Intravenous administration of 2 million of MSC/ kg",
                              "Intravenous administration of 4 million of MSC/ kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Intravenous administration of placebo",
                              "Drug: Intravenous administration of 1 million of MSC",
                              "Drug: Intravenous administration of 2 million of MSC",
                              "Drug: Intravenous administration of 4 million of MSC"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "1 million of MSC",
                              "2 million of MSC",
                              "4 million of MSC"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02290886"
                        ]
                  },
                  {
                        "Rank": 325,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: REcycled CartiLage Auto/Allo IMplantation"
                        ],
                        "ArmGroupLabel": [
                              "RECLAIM"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03672825"
                        ]
                  },
                  {
                        "Rank": 326,
                        "Acronym": [
                              "AUB001"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04642911"
                        ]
                  },
                  {
                        "Rank": 327,
                        "Acronym": [
                              "ADSCs-BWs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging",
                              "All patients will be subjected to standard stepped treatment of burn wounds:\n\nInfusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;\nSystemic antibiotic therapy for preventing infectious complications;\nAdequate analgesia and sedation;\nDecompression necrotomy in the first 24 hours following the burn trauma;\nNecrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;\nAutologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASCs"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASCs",
                              "The standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03113747"
                        ]
                  },
                  {
                        "Rank": 328,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intramuscular injection"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02208713"
                        ]
                  },
                  {
                        "Rank": 329,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Fat graft will be enriched with ex vivo expanded stem cells",
                              "Fat graft will not be enriched with ex vivo expanded stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Fat graft enriched with ex vivo expanded stem cells",
                              "Procedure: Fat graft not enriched with ex vivo expanded stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell enriched",
                              "Non stem cell enriched"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02494752"
                        ]
                  },
                  {
                        "Rank": 330,
                        "Acronym": [
                              "ADIPOSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients"
                        ],
                        "ArmGroupLabel": [
                              "Autologous ADRC injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03296501"
                        ]
                  },
                  {
                        "Rank": 331,
                        "Acronym": [
                              "BMAC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the autologous bone marrow aspirate concentrate. The contralateral knee will be injected with only sterile saline for placebo.",
                              "Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Bone Marrow Aspirate Concentrate",
                              "Drug: Sterile saline"
                        ],
                        "ArmGroupLabel": [
                              "Autologous bone marrow concentrate",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01931007"
                        ]
                  },
                  {
                        "Rank": 332,
                        "Acronym": [
                              "PD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Hope Biosciences adipose derived mesenchymal stem cells.",
                              "Sterile Saline Solution 0.9%"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs",
                              "Other: Placebo",
                              "Biological: HB-adMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04928287"
                        ]
                  },
                  {
                        "Rank": 333,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of autologous stromal vascular fraction on hand."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: injection of autologous stromal vascular fraction"
                        ],
                        "ArmGroupLabel": [
                              "Stromal vascular fraction injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02975960"
                        ]
                  },
                  {
                        "Rank": 334,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: aMSC",
                              "Biological: aMSC+hyaluronan gel"
                        ],
                        "ArmGroupLabel": [
                              "aMSC with and without hyaluronan gel"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01981330"
                        ]
                  },
                  {
                        "Rank": 335,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "historic cohort of patients with ABMR treated with standard of care therapy",
                              "patients with ABMR treated with MSC transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: MSC transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Historic control",
                              "MSC transplantation"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03585855"
                        ]
                  },
                  {
                        "Rank": 336,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transendocardial injection of placebo solution",
                              "transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: placebo intervention",
                              "Other: bone marrow-derived MSCs injection"
                        ],
                        "ArmGroupLabel": [
                              "placebo comparator",
                              "bone marrow-derived MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01957826"
                        ]
                  },
                  {
                        "Rank": 337,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The single injection of CS10BR05 Inj. in the carotid artery"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CS10BR05"
                        ],
                        "ArmGroupLabel": [
                              "CS10BR05"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03265444"
                        ]
                  },
                  {
                        "Rank": 338,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.",
                              "Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ARM 1: AdMSC: adipose stem cells",
                              "Other: ARM 2: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "ARM 1: AdMSC: adipose stem cells",
                              "ARM 2 Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02107118"
                        ]
                  },
                  {
                        "Rank": 339,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "20 million hMSCs .",
                              "40 million hMSCs",
                              "80 million hMSCs ."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: 20 million hMSCs",
                              "Drug: 40 million hMSCs",
                              "Drug: 80 million hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "low dose cohort",
                              "mid dose cohort",
                              "high dose cohort"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03455335"
                        ]
                  },
                  {
                        "Rank": 340,
                        "Acronym": [
                              "HULPVAS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight in a dosis"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Intramuscular injection of a suspension of adult mesenchymal stem cells derived"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01824069"
                        ]
                  },
                  {
                        "Rank": 341,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects in this Group will receive ReJoinTM injections on day 1 and day 22, and Sodium Hyaluronate injection on day 8 and day 15.",
                              "subjects in this group will receive Sodium Hyaluronate injections on day 1, 8, 15, 22."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ReJoinTM",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "ReJoinTM Group",
                              "Sodium Hyaluronate Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02855073"
                        ]
                  },
                  {
                        "Rank": 342,
                        "Acronym": [
                              "MESAMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Genetic: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intervention arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01076920"
                        ]
                  },
                  {
                        "Rank": 343,
                        "Acronym": [
                              "KNEEXO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The left knee will receive 1 million cells/kg SF-MSC-EX (Synovial fluid mesenchymal stem cell-derived exosome) by intra-articular injection method.",
                              "The right knee will receive 1 million cells/kg SF-MSC (Synovial fluid-derived mesenchymal stem cell) by intra-articular injection method.",
                              "Participants who received no treatment were defined as the control group."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: SF-MSC-EX",
                              "Drug: SF-MSC"
                        ],
                        "ArmGroupLabel": [
                              "SF-MSC-EX Treatment Group (Experimental group's left knees)",
                              "SF-MSC Treatment Group (Experimental group's right knees)",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05261360"
                        ]
                  },
                  {
                        "Rank": 344,
                        "Acronym": [
                              "A-ADAS-CT-CD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "lipoaspiration and transplantation of ADAS alone without scaffold",
                              "Lipoaspiration and transplantation of scaffold (human corneal decellularized lamina) without ADAS",
                              "Lipoaspiration and transplantation of ADAS cellularized on scaffold (the human corneal decellularized lamina)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Lipoaspiration",
                              "Procedure: Transplantation",
                              "Procedure: Lipoaspiration",
                              "Procedure: Transplantation",
                              "Procedure: Lipoaspiration",
                              "Procedure: Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "GROUP I",
                              "GROUP II",
                              "GROUP III"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02932852"
                        ]
                  },
                  {
                        "Rank": 345,
                        "Acronym": [
                              "TPAABPIHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous bone marrow mesenchymal stem cells (BMMSCs) with hypoxia pre-condition and endothelial pre-induction.",
                              "autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.",
                              "standard therapy without autologous bone marrow mesenchymal stem cells (BMMSCs) infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BMMSCs",
                              "Biological: BMMSCs",
                              "Biological: BMMSCs"
                        ],
                        "ArmGroupLabel": [
                              "pre-conditioned BMMSCs",
                              "BMMSCs",
                              "Controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02504437"
                        ]
                  },
                  {
                        "Rank": 346,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.",
                              "Subjects randomized to the placebo control group will undergo a \"sham\" bone marrow harvest."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous BMMNC Infusion",
                              "Biological: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Autologous BMMNC Infusion",
                              "Placebo Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02525432"
                        ]
                  },
                  {
                        "Rank": 347,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.",
                              "vildagliptin+metformin+pioglitazone and on Insulin >0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1",
                              "Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell transplantation",
                              "Other: control",
                              "Biological: MNC's TRANSPLANTATION"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell transplantation",
                              "Control",
                              "MNC's TRANSPLANTATION"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01759823"
                        ]
                  },
                  {
                        "Rank": 348,
                        "Acronym": [
                              "T2DM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.",
                              "30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MNC and UC-MSC",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "BM-MNC and UC-MSC",
                              "Stand medicines"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03943940"
                        ]
                  },
                  {
                        "Rank": 349,
                        "Acronym": [
                              "AMETIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Genetic: Autologous BMSCs transplantation",
                              "Genetic: Autologous EPCs transplantation",
                              "Genetic: IV infusion of placebo"
                        ],
                        "ArmGroupLabel": [
                              "BMSCs group",
                              "EPCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01468064"
                        ]
                  },
                  {
                        "Rank": 350,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "carrier plus in vitro expanded autologous BMSCs",
                              "Carrier alone"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: carrier plus in vitro expanded autologous BMSCs",
                              "Biological: carrier plus in vitro expanded autologous BMSCs"
                        ],
                        "ArmGroupLabel": [
                              "carrier plus BMSCs",
                              "carrier alone (control)."
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02177565"
                        ]
                  },
                  {
                        "Rank": 351,
                        "Acronym": [
                              "Measure"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00734396"
                        ]
                  },
                  {
                        "Rank": 352,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.",
                              "patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: stem cell therapy",
                              "Biological: stem cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "immediate stem cell therapy",
                              "delayed stem cell therapy"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01824121"
                        ]
                  },
                  {
                        "Rank": 353,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: adipose tissue derived stromal cells dosage"
                        ],
                        "ArmGroupLabel": [
                              "adipose tissue derived stromal cells"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01062750"
                        ]
                  },
                  {
                        "Rank": 354,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04681118"
                        ]
                  },
                  {
                        "Rank": 355,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion Cellgram\u2122(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cellgram\u2122 (Bone marrow-derived MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Cellgram\u2122 (Bone marrow-derived MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03838250"
                        ]
                  },
                  {
                        "Rank": 356,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
                              "hyaluronic acid"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: JointStem",
                              "Drug: Synvisc-One"
                        ],
                        "ArmGroupLabel": [
                              "JointStem",
                              "Synvisc-One"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02674399"
                        ]
                  },
                  {
                        "Rank": 357,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into rete testis."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Laboratory and Clinical"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02025270"
                        ]
                  },
                  {
                        "Rank": 358,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived MSCs",
                              "saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM",
                              "Drug: Saline"
                        ],
                        "ArmGroupLabel": [
                              "JOINTSTEM",
                              "Saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04821102"
                        ]
                  },
                  {
                        "Rank": 359,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: AstroStem",
                              "Other: Placebo-Control"
                        ],
                        "ArmGroupLabel": [
                              "AstroStem",
                              "Placebo-Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03117738"
                        ]
                  },
                  {
                        "Rank": 360,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Transplantation of purified autologous bone marrow-derived stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03067831"
                        ]
                  },
                  {
                        "Rank": 361,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: adipose tissue derived stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "adipose tissue derived stromal cells"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00913289"
                        ]
                  },
                  {
                        "Rank": 362,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Women who received breast reconstruction and autologous fat grafting.",
                              "Women who received breast reconstruction only."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous fat grafting procedure",
                              "Procedure: Breast reconstruction",
                              "Procedure: Breast reconstruction"
                        ],
                        "ArmGroupLabel": [
                              "Women receiving autologous fat grafting",
                              "Control"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04130373"
                        ]
                  },
                  {
                        "Rank": 363,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment group will be administered via intravenously AstroStem which consists of two syringes and each syringe contains 2.0 x 10^8 cells / 20 mL of saline with 30% auto-serum.",
                              "Placebo control group will receive AstroStem Placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AstroStem",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04482413"
                        ]
                  },
                  {
                        "Rank": 364,
                        "Acronym": [
                              "Bonecure"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HC-SVT-1001. Intraosseous use. 3x10(6) cells/cm3. (Initial protocol) HC-SVT-1002. Intraosseous use. 3x10(6) cells/cm3. (Protocol amendment)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)"
                        ],
                        "ArmGroupLabel": [
                              "Experimental"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02483364"
                        ]
                  },
                  {
                        "Rank": 365,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03226015"
                        ]
                  },
                  {
                        "Rank": 366,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "POF cases were evaluated hormonally, HP and IH using ESS. Autologous MSC were prepared and laparoscopically transplanted."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cell therapy in POF"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02372474"
                        ]
                  },
                  {
                        "Rank": 367,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.",
                              "Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Aspirate Concentrate",
                              "Procedure: Standard Meniscectomy",
                              "Procedure: Standard Meniscectomy"
                        ],
                        "ArmGroupLabel": [
                              "Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)",
                              "Meniscectomy with Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02582489"
                        ]
                  },
                  {
                        "Rank": 368,
                        "Acronym": [
                              "ANTG"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group1. Low dose group",
                              "Group2. High dose group"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose derived stem cells(low dose group)",
                              "Biological: Autologous adipose derived stem cells(high dose group)"
                        ],
                        "ArmGroupLabel": [
                              "Low dose group",
                              "High dose group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01623453"
                        ]
                  },
                  {
                        "Rank": 369,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived MSCs",
                              "Sodium chloride"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM",
                              "Drug: Saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Jointstem",
                              "Saline solution"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02658344"
                        ]
                  },
                  {
                        "Rank": 370,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous BM transplant",
                              "conventional physical therapy for chronic spinal cord injury."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous bone marrow transplant",
                              "Procedure: Physical therapy",
                              "Procedure: Physical therapy"
                        ],
                        "ArmGroupLabel": [
                              "BM transplant with physiotherapy",
                              "Physiotherapy only"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00816803"
                        ]
                  },
                  {
                        "Rank": 371,
                        "Acronym": [
                              "BME-TARGET"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).",
                              "i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.",
                              "injections of autologous BMC."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: core decompression",
                              "Biological: bone substitute i-FactorTM",
                              "Biological: autologous bone marrow concentrate"
                        ],
                        "ArmGroupLabel": [
                              "core decompression technique",
                              "bone substitution (i-FactorTM)",
                              "injections of autologous Bone Marrow Concentrate (BMC)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03112122"
                        ]
                  },
                  {
                        "Rank": 372,
                        "Acronym": [
                              "BMT-POI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous bone marrow will be given by intravenous infusion. the intervention will be preceded by a period of 6 months of follow up the a period of 12 months follow up"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous bone marrow transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous bone marrow transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02779374"
                        ]
                  },
                  {
                        "Rank": 373,
                        "Acronym": [
                              "EPIMSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous ADRC transplantation in autoimmune refractory epilepsy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ADRC transplantation in autoimmune refractory epilepsy"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03676569"
                        ]
                  },
                  {
                        "Rank": 374,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Maximal amount of MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02304588"
                        ]
                  },
                  {
                        "Rank": 375,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get no stem cell infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologus Mesenchymal Stem Cells",
                              "Allogeniec Mesenchymal Stem Cells",
                              "Control without Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02409940"
                        ]
                  },
                  {
                        "Rank": 376,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)",
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)",
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intra-articular injection of ADMSC",
                              "Biological: Intra-articular injection of ADMSC",
                              "Biological: Intra-articular injection of ADMSC"
                        ],
                        "ArmGroupLabel": [
                              "osteoarthritis of the knee",
                              "osteoarthritis of the hip",
                              "osteoarthritis of the glenohumeral joint"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03869229"
                        ]
                  },
                  {
                        "Rank": 377,
                        "Acronym": [
                              "MSV_allo"
                        ],
                        "AgreementOtherDetails": [
                              "The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.",
                              "Intraarticular injection of hyaluronic acid (60 mg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Allogenic mesenchymal stromal cells injection",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic mesenchymal stromal cells injection",
                              "Hyaluronic acid (Durolane)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01586312"
                        ]
                  },
                  {
                        "Rank": 378,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cell infusion and bone marrow mononuclear cell infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell infusion",
                              "Biological: bone marrow mononuclear cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00813267"
                        ]
                  },
                  {
                        "Rank": 379,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Non-cultured Autologous Keratinocyte Suspension",
                              "Adipose-Derived Stem cell-Keratinocyte Suspension",
                              "Split skin graft"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Non-cultured Autologous Keratinocyte Suspension",
                              "Procedure: Adipose-Derived Stem cell-Keratinocyte Suspension",
                              "Procedure: Split skin graft"
                        ],
                        "ArmGroupLabel": [
                              "study group 1",
                              "study group 2",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03686449"
                        ]
                  },
                  {
                        "Rank": 380,
                        "Acronym": [
                              "Disc_allo"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline",
                              "Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic Mesenchymal Stromal Cells",
                              "Drug: Mepivacaine"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic Mesenchymal Stromal Cells",
                              "Mepivacaine"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01860417"
                        ]
                  },
                  {
                        "Rank": 381,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient enrolled from emergency room or outpatient population undergo pre-operatory tests including blood test, thoracic radiography, electrocardiogram, cardiologic visit, TcPO2 measurement and Doppler ultrasonography. During surgery the terminal branches of the patient's leg arteries are mapped and under local anesthesia multiple injections (1 mL each) of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries. Furthermore, a total amount of 0.5-1 ml of the autologous adipose tissue-derived cell (ATDC) fraction is injected 1 cm near to ischaemic lesions.\n\nAfter the surgical procedure, the patient will be followed for 6 months, during which he will undergo outpatient visits at 7 and 21 days; then at 1, 3 and 6 months. At each visit, the patient will be assessed for the amount of pain, the transcutaneous oximetry value, measurement of the ABI index, arterial ultrasound Doppler lower limbs."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Fat Grafting"
                        ],
                        "ArmGroupLabel": [
                              "Patients with critic limb ischemia"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04746599"
                        ]
                  },
                  {
                        "Rank": 382,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intraarticular injection of Hyaluronic acid (Hyal One)",
                              "Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells",
                              "Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Hyaluronic acid",
                              "Drug: Hyaluronic acid",
                              "Biological: 10 million Bone marrow mesenchimal stem cells",
                              "Drug: Hyaluronic acid",
                              "Biological: 100 million Bone marrow mesenchimal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Hialuronic acid",
                              "Hyaluronic acid and MSC 10",
                              "Hyaluronic acid AND MSC 100"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02123368"
                        ]
                  },
                  {
                        "Rank": 383,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: ASC enriched lipofilling",
                              "Biological: Standard Lipofilling"
                        ],
                        "ArmGroupLabel": [
                              "ASC",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03258164"
                        ]
                  },
                  {
                        "Rank": 384,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: adipose tissue derived stromal cells dosage"
                        ],
                        "ArmGroupLabel": [
                              "adipose tissue derived stromal cells"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01709279"
                        ]
                  },
                  {
                        "Rank": 385,
                        "Acronym": [
                              "FISPAC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.",
                              "Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: \u25e6Drug: ASCs. + fibrin glue",
                              "Drug: fibrin glue"
                        ],
                        "ArmGroupLabel": [
                              "ASC + fibrin glue",
                              "Fibrin glue"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01803347"
                        ]
                  },
                  {
                        "Rank": 386,
                        "Acronym": [
                              "EB-CMF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subject receiving EB-CMF implant"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: EB-CMF"
                        ],
                        "ArmGroupLabel": [
                              "EB-CMF Implant"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03678467"
                        ]
                  },
                  {
                        "Rank": 387,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous mononuclear stem cell from the bone marrow in an unique infusion of 150-250 millions of cells",
                              "Autologous endothelial progenitor CD133 stem cell from the bone marrow in an unique infusion of 2 - 7 millions of CD133 cells",
                              "Autologous mesenchymal stem cells from the adipose tissue in an unique infusion of 0.5 millions of cells",
                              "Current medication for the disease"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Stem cell infusion",
                              "Drug: Stem cell infusion",
                              "Drug: Stem cell infusion",
                              "Drug: Stem cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mononuclear stem cell from the bone marrow",
                              "Autologous endothelial stem cell from the bone marrow",
                              "Autologous mesenchymal stem cells from the adiposite tissue",
                              "Current medication for the disease"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02287974"
                        ]
                  },
                  {
                        "Rank": 388,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous administration of purified autologous bone marrow-derived stem cells.",
                              "Intrathecal administration of purified autolgous bone-marrow derived stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cell Transplantation",
                              "Biological: Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells",
                              "Stem Cell Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03069170"
                        ]
                  },
                  {
                        "Rank": 389,
                        "Acronym": [
                              "ASPEFIC1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous adipose-derived stem cells (ASCs) injection with LIPOGEMS system."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: ASCs injection",
                              "Device: ASCs injection",
                              "Device: Closure of fistula tract."
                        ],
                        "ArmGroupLabel": [
                              "ASCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02403232"
                        ]
                  },
                  {
                        "Rank": 390,
                        "Acronym": [
                              "CMM-PRGF/ART"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.",
                              "Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Platelet Rich plasma (PRGF)",
                              "Biological: 100 million Bone marrow mesenchimal stem cells",
                              "Biological: Platelet Rich plasma (PRGF)"
                        ],
                        "ArmGroupLabel": [
                              "Platelet Rich Plasma (PRGF)",
                              "BMMSC with Platelet Rich Plasma (PRGF)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02365142"
                        ]
                  },
                  {
                        "Rank": 391,
                        "Acronym": [
                              "IMPACT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Cartilage repair surgery"
                        ],
                        "ArmGroupLabel": [
                              "Cartilage repair surgery"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02037204"
                        ]
                  },
                  {
                        "Rank": 392,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive no interventions after rectal cancer treatment.",
                              "Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.",
                              "Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.",
                              "Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Laparoscopic surgery",
                              "Device: NeuroRegen scaffold transplantation",
                              "Biological: NeuroRegen scaffold/BMMCs transplantation",
                              "Biological: NeuroRegen scaffold/HUC-MSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Laparoscopic surgery",
                              "NeuroRegen scaffold transplantation",
                              "NeuroRegen scaffold/BMMCs transplantation",
                              "NeuroRegen scaffold/HUC-MSCs transplantation"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02648386"
                        ]
                  },
                  {
                        "Rank": 393,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "standard treatment according to clinical protocols plus mesenchymal stem cells",
                              "standard treatment according to clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Other: standard treatment",
                              "Other: standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04446897"
                        ]
                  },
                  {
                        "Rank": 394,
                        "Acronym": [
                              "MESRIX"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the MSC-suspension , the surgeon will identify the submandibular glands and inject the suspension MSCs into the submandibular gland. Calculation of injected number of MSCs pr. participant rests on the following calculation: 2.8 x 10^6 MSC / Cm^3 X volume , where volume is the volume of the submandibular gland, and a gland-volume of app. 7-8cm3 is the norm. Therefore the amount of cells given to each participant will be app. 4.6 x 10^7 MSC in total. Afterwards the participant will be given a band-aid and over the counter analgesics.",
                              "The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the placebo-suspension , the surgeon will identify the submandibular glands and inject the suspension. Placebo will be 2ml of Isotonic NaCl (0,9mg/ml) and HA 1%."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cell",
                              "Drug: Isotonic NaCl"
                        ],
                        "ArmGroupLabel": [
                              "Stemcells injected into submandibularis",
                              "Saltwater injected into submandibularis"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02513238"
                        ]
                  },
                  {
                        "Rank": 395,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stromal cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell"
                        ],
                        "ArmGroupType": [
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00260338"
                        ]
                  },
                  {
                        "Rank": 396,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The lesion will be treated with curettage then 1 million of bone marrow derived MSC seeded on 5x5 mm2 PLGA scaffold will be engrafted in the cyst of ABC patient."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC-PLGA"
                        ],
                        "ArmGroupLabel": [
                              "MSC-PLGA"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03066245"
                        ]
                  },
                  {
                        "Rank": 397,
                        "Acronym": [
                              "UB-OVF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04675970"
                        ]
                  },
                  {
                        "Rank": 398,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient group receiving the stem cell injections during the CABG",
                              "The patient group receiving autologous serum injections during the CAGB operation"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Coronary bypass operation",
                              "Procedure: Bone marrow aspiration (crista iliaca)",
                              "Biological: Intramyocardial mesenchymal stem cell transplantation",
                              "Procedure: Coronary bypass operation",
                              "Procedure: Bone marrow aspiration (crista iliaca)",
                              "Biological: Intramyocardial injection of autologous serum"
                        ],
                        "ArmGroupLabel": [
                              "A",
                              "B"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00418418"
                        ]
                  },
                  {
                        "Rank": 399,
                        "Acronym": [
                              "Bone-Gun"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04310852"
                        ]
                  },
                  {
                        "Rank": 400,
                        "Acronym": [
                              "CELLCORDES2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery",
                              "Adults with Scarred vocal folds, congenital (sulcus) or after phonosurgery"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "ADSVF group",
                              "Placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05385159"
                        ]
                  },
                  {
                        "Rank": 401,
                        "Acronym": [
                              "GVHD-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01549665"
                        ]
                  },
                  {
                        "Rank": 402,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive 25 x 10^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.",
                              "Patients will undergo marrow cellution surgical procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Procedure: Marrow cellution"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Marrow cellution (standard treatment)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05016011"
                        ]
                  },
                  {
                        "Rank": 403,
                        "Acronym": [
                              "MESEMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0",
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Drug: Suspension media"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Suspension media"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02403947"
                        ]
                  },
                  {
                        "Rank": 404,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.\nADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ADSTEM Inj. (Adult human mesenchymal stem cells)"
                        ],
                        "ArmGroupLabel": [
                              "intervention: Biological: ADSTEM Inj."
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02888704"
                        ]
                  },
                  {
                        "Rank": 405,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Repair of cranial defects by tissue engineering"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Repair of cranial defects by tissue engineering"
                        ],
                        "ArmGroupLabel": [
                              "Repair of cranial defect"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01742260"
                        ]
                  },
                  {
                        "Rank": 406,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cartilage defect are treated surgical either with chondrocytes or stem cells",
                              "Active rehabilitation program"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: stem cells",
                              "Procedure: Chondrocytes",
                              "Other: Rehabilitation program"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells",
                              "Rehabilitation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00885729"
                        ]
                  },
                  {
                        "Rank": 407,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous bone marrow aspirate is taken under local anesthesia to be centrifuged and the concentrate given intra articularly in knee joint",
                              "control group given analgesics only"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: autologous bone marrow aspirate concentrate by centrifugation",
                              "Procedure: autologous bone marrow aspirate concentrate by centrifugation"
                        ],
                        "ArmGroupLabel": [
                              "treatment with autologous bone marrow aspirate concentrate",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05193877"
                        ]
                  },
                  {
                        "Rank": 408,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The cases assigned to this group will be injected intra-articularly with Lipogems\u00ae. The patients will undergo harvesting of their own adipose tissue for aMAT then this aMAT will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study.",
                              "The cases assigned to this group will be injected intra-articularly in the knee with corticosteroids. No extra preparation of any type is necessary in this case. It will be administered once at the baseline visit of the study."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Microfragmented Adipose Tissue Transplant",
                              "Drug: Corticosteroid injection"
                        ],
                        "ArmGroupLabel": [
                              "Lipogems",
                              "Steroid"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04230902"
                        ]
                  },
                  {
                        "Rank": 409,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional therapy plus MenSCs treatment",
                              "Conventional therapy plus placebo treatment:\n\nOral or intravenous administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: conventional therapy plus MenSC transplantation",
                              "Drug: Conventional therapy plus placebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "Intervention",
                              "No intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01483248"
                        ]
                  },
                  {
                        "Rank": 410,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement",
                              "SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Control group",
                              "Procedure: SVF group"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "SVF group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05270850"
                        ]
                  },
                  {
                        "Rank": 411,
                        "Acronym": [
                              "RIMECARD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord derived mesenchymal are injected intravenously to Patients.",
                              "Intravenous placebo solution are administrated to Patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ucMSC",
                              "Other: Controls"
                        ],
                        "ArmGroupLabel": [
                              "ucMSC",
                              "Controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01739777"
                        ]
                  },
                  {
                        "Rank": 412,
                        "Acronym": [
                              "BioMiStem-CT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)",
                              "The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)",
                              "The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)",
                              "The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)",
                              "The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)",
                              "The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MesoCellA-Ortho administration",
                              "Drug: HA administration",
                              "Drug: MesoCellA-Ortho administration",
                              "Drug: HA administration",
                              "Drug: MesoCellA-Ortho administration",
                              "Drug: HA administration"
                        ],
                        "ArmGroupLabel": [
                              "MesoCellA-Ortho - treated Patients with type 2 diabetes and with obesity",
                              "Control Patients with type 2 diabetes and obesity",
                              "MesoCellA-Ortho - treated Patients without type 2 diabetes and with obesity",
                              "Control Patients without type 2 diabetes and with obesity",
                              "MesoCellA-Ortho - treated Patients without type 2 diabetes and without obesity",
                              "Control Patients without type 2 diabetes and without obesity"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05081921"
                        ]
                  },
                  {
                        "Rank": 413,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous hematopoietic and/or mesenchymal stem cells transduced with lentiviral vector carrying the ADA gene"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: TYF-ADA gene-modified autologous stem cells"
                        ],
                        "ArmGroupLabel": [
                              "TYF-ADA-modified autologous stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03645460"
                        ]
                  },
                  {
                        "Rank": 414,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSCs by peripheral intravenous infusion",
                              "received hormone maintenance therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: UC-MSCs by peripheral intravenous infusion",
                              "Drug: received hormone maintenance therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02445547"
                        ]
                  },
                  {
                        "Rank": 415,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "5 Patients with cleft unilateral lip and palate that have already performed the alignment of dental arches through the recommended orthodontic treatment will be selected to be submited to alveolar bone tissue engineering surgery"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: maxillary alveolar graft by tissue engineering",
                              "Procedure: Bone tissue engineering using mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "cleft lip and palate"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01932164"
                        ]
                  },
                  {
                        "Rank": 416,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "micro injection of Stromal Vascular Fraction extracted from autologous adipose tissue in vocal cords"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: micro injection of SVF in vocal cords"
                        ],
                        "ArmGroupLabel": [
                              "micro injection of SVF in vocal cords"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02622464"
                        ]
                  },
                  {
                        "Rank": 417,
                        "Acronym": [
                              "AMIPREP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: injection of microfat and plasma rich platelet PRP",
                              "Device: MRI"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03164122"
                        ]
                  },
                  {
                        "Rank": 418,
                        "Acronym": [
                              "CHART-1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Sham, no injection",
                              "Injection of C3BS-CQR-1"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Sham, no injection",
                              "Biological: Injection of C3BS-CQR-1"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "C3BS-CQR-1 Treated"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01768702"
                        ]
                  },
                  {
                        "Rank": 419,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "SC therapy,'Bone Marrow Stimulation','CD34+ autologous stem cell transplantation':\n\nIn the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect",
                              "Patients receiving no cell therapy."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CD34+ autologous stem cell transplantation",
                              "Drug: Bone Marrow Stimulation",
                              "Biological: SC therapy"
                        ],
                        "ArmGroupLabel": [
                              "SC Group",
                              "Controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00629018"
                        ]
                  },
                  {
                        "Rank": 420,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Core decompression/PREOB\u00ae implantation",
                              "Drug: Core decompression/placebo implantation"
                        ],
                        "ArmGroupLabel": [
                              "Core decompression/PREOB\u00ae implantation",
                              "Core decompression/placebo implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Caucasian/White",
                              "Black",
                              "Oriental/Asian",
                              "Hispanic",
                              "Other"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01529008"
                        ]
                  },
                  {
                        "Rank": 421,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.",
                              "Gel-One\u00ae is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BMAC injection",
                              "Biological: PRP injection",
                              "Device: Gel-One\u00ae hyaluronate injection"
                        ],
                        "ArmGroupLabel": [
                              "BMAC injection and PRP injection",
                              "Gel-One\u00ae hyaluronate injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT02958267"
                        ]
                  },
                  {
                        "Rank": 422,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In 20 patients who have stable vitiligo with the duration of stability more than 3 months, non cultured epidermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and non cultured epidermal cell suspension will be done.",
                              "In 20 patients who have stable vitiligo with the duration of stability more than 3 months, combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Non cultured epidermal cell suspension",
                              "Procedure: Non cultured epidermal cell suspension",
                              "Procedure: Non cultured dermal cell suspension"
                        ],
                        "ArmGroupLabel": [
                              "Non cultured epidermal cell suspension",
                              "Non cultured dermal cell suspension"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03013049"
                        ]
                  },
                  {
                        "Rank": 423,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01557543"
                        ]
                  },
                  {
                        "Rank": 424,
                        "Acronym": [
                              "MSCGVHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00749164"
                        ]
                  },
                  {
                        "Rank": 425,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group of patients with complete transection of the spinal cord group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive AutoBM-MSCs by a specialized spine surgeon into the spinal medulla.",
                              "This group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive WJ-MSCs by a specialized spine surgeon into the spinal medulla."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Collection and expansion of BM-MSC",
                              "Diagnostic Test: VI-SCI evaluation and patients' follow up",
                              "Biological: Collection and expansion of BM-MSC",
                              "Diagnostic Test: VI-SCI evaluation and patients' follow up"
                        ],
                        "ArmGroupLabel": [
                              "patients with complete transection of the spinal cord",
                              "patients with SCI without total transaction."
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04288934"
                        ]
                  },
                  {
                        "Rank": 426,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous hematopoeitic stem cells and mesenchymal stem cells transduced with lentiviral vector carrying the FANCA gene ex vivo"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Gene-modified autologous stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Gene-modified autologous stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03351868"
                        ]
                  },
                  {
                        "Rank": 427,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A total of 11patients ( november 2012 to august 2018) with atrophic non-union of long bones already treated with percutaneous SVF implantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose tissue derived stromal vascular fraction (SVF)"
                        ],
                        "ArmGroupLabel": [
                              "Patients with nonunion of long bones"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04340284"
                        ]
                  },
                  {
                        "Rank": 428,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Device: Lipogems"
                        ],
                        "ArmGroupLabel": [
                              "injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03788265"
                        ]
                  },
                  {
                        "Rank": 429,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cord blood transplantation performed on day 0. Busulfan 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4.\n\nFludarabine 10 mg/m2 by vein on Days -7 to -4, 40 mg/m2 by vein on Days -6 to -3 or on Days -5 to -2.\n\nRituximab 375 mg/m2 by vein on Day -9. ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3, 1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2.\n\nCyclophosphamide 50 mg/kg by vein on Day -6. Clofarabine 30 mg/m2 by vein on Days -7 to -4. Total body irradiation (TBI) 200 cGy at 25 cGy/minute delivered on Day -3. Melphalan 140 mg/m2 by vein on Day -2. Tacrolimus 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Cord Blood Infusion",
                              "Drug: Busulfan",
                              "Drug: Fludarabine",
                              "Drug: Rituximab",
                              "Other: ATG",
                              "Drug: Cyclophosphamide",
                              "Drug: Clofarabine",
                              "Radiation: Total Body Irradiation (TBI)",
                              "Drug: Melphalan",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil",
                              "Drug: G-CSF"
                        ],
                        "ArmGroupLabel": [
                              "Cord Blood Infusion"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00498316"
                        ]
                  },
                  {
                        "Rank": 430,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1: Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells",
                              "Group 2: Patients with Type 1 Diabetes Mellitus receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous tolerogenic dendritic cells",
                              "Other: Standard treatment according to the clinical protocols",
                              "Other: Standard treatment according to the clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells",
                              "Patients with Type 1 Diabetes Mellitus receiving standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05207995"
                        ]
                  },
                  {
                        "Rank": 431,
                        "Acronym": [
                              "PREOB-ON2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Core decompression/autologous osteoblastic cells (PREOB\u00ae) implantation",
                              "Core decompression/bone marrow concentrate (BMC) implantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Core decompression/PREOB\u00ae implantation",
                              "Drug: Core decompression/BMC implantation"
                        ],
                        "ArmGroupLabel": [
                              "Core decompression/PREOB\u00ae implantation",
                              "Core decompression/BMC implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02890537"
                        ]
                  },
                  {
                        "Rank": 432,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group wil receive 8 intravenous infusions of mesenchymal stem cells. Four infusions 1 week apart and 4 infusions a month apart"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous Mesenchymal stem cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01322789"
                        ]
                  },
                  {
                        "Rank": 433,
                        "Acronym": [
                              "ROBUST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800\u00ae cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;",
                              "open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Cellularized composite graft augmentation",
                              "Procedure: Acellular composite graft augmentation"
                        ],
                        "ArmGroupLabel": [
                              "cellularized composite graft augmentation",
                              "Control acellular composite graft augmentation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01532076"
                        ]
                  },
                  {
                        "Rank": 434,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Injection of autologous regenerative cells of adipose tissue"
                        ],
                        "ArmGroupLabel": [
                              "study group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03643614"
                        ]
                  },
                  {
                        "Rank": 435,
                        "Acronym": [
                              "MSC/ONM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with definite diagnosis of osteonecrosis of the jaw by clinical and radiological examination of any etiology will receive a construct made of Bone Marrow Stem Cell + Tricalcium Phosphate + Demineralized Bone Matrix (MSC+TP+DBM)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC construct for Osteonecrosis"
                        ],
                        "ArmGroupLabel": [
                              "MSC construct for Osteonecrosis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02566681"
                        ]
                  },
                  {
                        "Rank": 436,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AlloStem is the combination of the Mesenchymal Stem Cells (MSC) derived from adipose with demineralized bone.",
                              "Autologous bone graft is recovered from the patient's own tibia or iliac crest, for transplantation in the subtalar joint."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Subtalar Arthrodesis",
                              "Procedure: Subtalar Arthrodesis"
                        ],
                        "ArmGroupLabel": [
                              "AlloStem Live Cellular Allograft",
                              "Control: Autologous Bone Marrow Aspirate"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01413061"
                        ]
                  },
                  {
                        "Rank": 437,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs Participants will received i. m. HUC-MSCs both lower extremities",
                              "The control group will receive i.v Lipoic Acid Injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HUC-MSCs",
                              "Biological: Lipoic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05507697"
                        ]
                  },
                  {
                        "Rank": 438,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04772378"
                        ]
                  },
                  {
                        "Rank": 439,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cells plus standard conservative care.",
                              "Standard Conventional Treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose Tissue derived Total-Stromal-Cells (TOST)"
                        ],
                        "ArmGroupLabel": [
                              "Adipose Tissue derived Total-Stromal-Cells (TOST)",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05280002"
                        ]
                  },
                  {
                        "Rank": 440,
                        "Acronym": [
                              "REGEN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100 million human MSCs in 200mls of normal saline, intravenously, once-off, over 1-2hours"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human Mesenchymal Stem Cell (MSC) infusion therapy"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Population"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04174898"
                        ]
                  },
                  {
                        "Rank": 441,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.",
                              "participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: conventional plus MSC treatment",
                              "Drug: conventional plus placebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "conventional plus MSC treatment",
                              "conventional plus placebo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01220492"
                        ]
                  },
                  {
                        "Rank": 442,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Outpatient in hospital",
                              "interventions: rehabilitation",
                              "interventions: stem cell transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: rehabilitation of limb function",
                              "Procedure: Stem Cells Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "control",
                              "rehabilitation",
                              "Stem Cell Transplantation"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01393977"
                        ]
                  },
                  {
                        "Rank": 443,
                        "Acronym": [
                              "SCI-III"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.",
                              "Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.",
                              "Patients receive no professional treatment in hospital or rehabilitation centre."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: rehabilitation",
                              "Biological: cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "rehabilitation",
                              "cell therapy",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01873547"
                        ]
                  },
                  {
                        "Rank": 444,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients receive arthroscopic repair with bone marrow concentration.",
                              "The patients receive arthroscopic repair only"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: arthroscopic repair with bone marrow concentration",
                              "Other: arthroscopic repair"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow concentration group",
                              "Historical control group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03792594"
                        ]
                  },
                  {
                        "Rank": 445,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Consecutive patients receive intramedullary nail fixation with bone marrow concentration.",
                              "Previous age- and gender-matched patients who receive intramedullary nail fixation only."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: intramedullary nail fixation with bone marrow concentration",
                              "Other: intramedullary nail fixation"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow concentration group",
                              "Historical control group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03794622"
                        ]
                  },
                  {
                        "Rank": 446,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients receive core decompression surgery with bone marrow concentration.",
                              "The previous age-, gender-, and stage-matched patients who received core decompression surgery only."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Core decompression surgery with bone marrow concentration",
                              "Other: Core decompression surgery"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow concentration group",
                              "Historical control group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03787329"
                        ]
                  },
                  {
                        "Rank": 447,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "20 individuals will receive placebo.",
                              "Active combination autologous stem cell therapy. 40 individuals will receive MESENDO in either the \"high\" or \"low\" dose treatment groups."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: placebo",
                              "Biological: MESENDO"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "MESENDO"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00790764"
                        ]
                  },
                  {
                        "Rank": 448,
                        "Acronym": [
                              "ARTHROSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: arthroplasty"
                        ],
                        "ArmGroupLabel": [
                              "Surgical intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01879046"
                        ]
                  },
                  {
                        "Rank": 449,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be transfused into 20 COPD patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02645305"
                        ]
                  },
                  {
                        "Rank": 450,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "the mesenchymal cells will be separated by sepax separation system and demineralized bone matrix will be done using IGNITE INJECTABLE REPAIR GRAFT"
                        ],
                        "ArmGroupInterventionName": [
                              "Device: the Sepax is a tool to standardize adult stem cell. Ignite \u00aeICS injectable scaffold manufactured by Wright Medical Technology."
                        ],
                        "ArmGroupLabel": [
                              "sepax, ignite, fracture healing"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01435434"
                        ]
                  },
                  {
                        "Rank": 451,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Lipogems injection in the internal orifice, mucosal, submucosal and muscular layer, in the fistula tract and external orifice."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Lipogems"
                        ],
                        "ArmGroupLabel": [
                              "Lipogems"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03913910"
                        ]
                  },
                  {
                        "Rank": 452,
                        "Acronym": [
                              "HULPCIR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intralesional application"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose-derived stem cells without expanded"
                        ],
                        "ArmGroupLabel": [
                              "Autologous SVF"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01548092"
                        ]
                  },
                  {
                        "Rank": 453,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients from this group will be treated with a combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) prepared with the Cellular Matrix / A-CP HA medical device",
                              "Patients from this group will be treated with a well-recognized hyaluronic acid named Ostenil\u00ae Plus",
                              "Patients from this group will be treated with PRP alone, prepared with RegenKit-BCT-1"
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Cellular Matrix / A-CP HA",
                              "Device: Ostenil\u00ae Plus",
                              "Device: RegenKit-BCT-1"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group 1",
                              "Control group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02964143"
                        ]
                  },
                  {
                        "Rank": 454,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The control group (Group K) is comprised of surgical patients who will not receive blood transfusion, and who have contraindications for Tranexamic Acid.",
                              "The treatment group (Group A) is comprised of the patients who will receive Tranexamic acid 1g intravenous 15 min. before releasing the pneumatic tourniquet and the repeating dose 3 hours later",
                              "The treatment group (Group B) will be comprised of the patients who in the second selection have one or more contraindications for Tranexamic Acid administration and transfusion of autologous blood will be performed.",
                              "The treatment group (Group C) contraindications for Tranexamic Acid administration and the transfusion of alogenous blood will be performed in the case of acute haemorrhage followed by patient's hemodynamic instability."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Tranexamic Acid",
                              "Drug: Tranexamic Acid",
                              "Drug: Tranexamic Acid"
                        ],
                        "ArmGroupLabel": [
                              "The control group (Group K)",
                              "Group A, Tranexamic acid",
                              "Group B, autologous transfusion",
                              "Group C, alogenous transfusion"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Active Comparator",
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03795649"
                        ]
                  },
                  {
                        "Rank": 455,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Lipogems - local injection of autologous micro-fragmented adipose tissue",
                              "Routine clinical practice"
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Lipogems"
                        ],
                        "ArmGroupLabel": [
                              "Intervention",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03276312"
                        ]
                  },
                  {
                        "Rank": 456,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: SVF injection"
                        ],
                        "ArmGroupLabel": [
                              "SVF injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Diffuse",
                              "Limited"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000"
                        ],
                        "NCTId": [
                              "NCT03060551"
                        ]
                  },
                  {
                        "Rank": 457,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04825626"
                        ]
                  },
                  {
                        "Rank": 458,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).\n\nMaximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ABMD-MSC"
                        ],
                        "ArmGroupLabel": [
                              "ABDM-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01686139"
                        ]
                  },
                  {
                        "Rank": 459,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04064983"
                        ]
                  },
                  {
                        "Rank": 460,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will include 20 patients with liver cirrhosis, autologous bone marrow derived mesenchymal stem cells will be transplanted to them. Every patient will receive 2 million cells per Kg via portal vein once.",
                              "This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell transplantation",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02943889"
                        ]
                  },
                  {
                        "Rank": 461,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01668576"
                        ]
                  },
                  {
                        "Rank": 462,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants in this arm will have autologous stem cells harvested through bone marrow aspiration. The stem cells that were harvested will be processed and injected into affected intradiscal spaces in the lumber spine.",
                              "Participants in this arm will receive an intradiscal injection of the steroid methylprednisolone and the local anesthetic bupivacaine into affected intradiscal spaces in the lumber spine."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous stem cells",
                              "Drug: Corticosteroid",
                              "Drug: Local anesthetic"
                        ],
                        "ArmGroupLabel": [
                              "Intradiscal autologous stem cells",
                              "Intradiscal corticosteroid and local anesthetic"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04735185"
                        ]
                  },
                  {
                        "Rank": 463,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05154851"
                        ]
                  },
                  {
                        "Rank": 464,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment established by the good clinical practice Patients received standard local care dressing method (compresses) to heal leg ulcers",
                              "Intramuscular implantation of Autologous bone marrow-derived mononuclear cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of Autologous Bone Marrow Mononuclear Cells"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Stem Cell Injection"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02619734"
                        ]
                  },
                  {
                        "Rank": 465,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive standard of care hip decompression along with an injection of approximately 5 mls. of lactated ringers.",
                              "Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Lactated Ringers",
                              "Device: The Celution 800/GP System (Cytori Therapeutics)",
                              "Biological: Adipose Derived Regenerative Cells (ADRC)"
                        ],
                        "ArmGroupLabel": [
                              "Hip Decompression with lactated ringers",
                              "Hip Decompression with ADRC"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03269409"
                        ]
                  },
                  {
                        "Rank": 466,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "core decompression + bone marrow implantation into the necrotic lesion",
                              "core decompression"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: core decompression",
                              "Procedure: Bone marrow implantation into the necrotic lesion",
                              "Procedure: core decompression"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow graft group",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00821470"
                        ]
                  },
                  {
                        "Rank": 467,
                        "Acronym": [
                              "TENDO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: mesenchymal stem cells",
                              "Procedure: Pure platelet-rich plasma"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Pure platelet-rich plasma"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03454737"
                        ]
                  },
                  {
                        "Rank": 468,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Biological: Bone marrow-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe"
                        ],
                        "ArmGroupLabel": [
                              "Hyaluronic Acid (HA) + P-MMSCs",
                              "Hyaluronic Acid (HA) + BM-MMSCs",
                              "Hyaluronic Acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04453111"
                        ]
                  },
                  {
                        "Rank": 469,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "BRTX-100 consists of a population of hypoxic-cultured bone marrow mononuclear cells highly enriched in mesenchymal stem cells from autologous bone marrow with autologous platelet lysate.",
                              "Isotonic saline will be used as a control in this study. Drug: saline (0.9% sodium chloride)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BRTX-100",
                              "Drug: Saline"
                        ],
                        "ArmGroupLabel": [
                              "Active Treatment- BRTX-100",
                              "Saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04042844"
                        ]
                  },
                  {
                        "Rank": 470,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.\n\nBMAC application at the time of arthroscopic labral repair.",
                              "Patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to arthroscopic labral tear repair.\n\nNo BMAC application at the time of arthroscopic labral repair."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BMAC"
                        ],
                        "ArmGroupLabel": [
                              "BMAC Application",
                              "No BMAC Application"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03909139"
                        ]
                  },
                  {
                        "Rank": 471,
                        "Acronym": [
                              "Fistula_CM1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with complex anal fistulas, non related to Crohn's disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Adipose tissue injection associated with endorectal advancement flap."
                        ],
                        "ArmGroupLabel": [
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04750499"
                        ]
                  },
                  {
                        "Rank": 472,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients received standard of care wound treatment according guideline of the American Diabetes Association (ADA)",
                              "bone marrow stem cells administered intraarterial",
                              "expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intramuscular",
                              "expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intraarterial",
                              "bone marrow stem cells administered intramuscular"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow stem cells (BMC)",
                              "Biological: tissue repair cells (TRC)",
                              "Biological: tissue repair cells (TRC)",
                              "Biological: bone marrow stem cells (BMC)"
                        ],
                        "ArmGroupLabel": [
                              "control group",
                              "bone marrow stem cells intraarterial",
                              "tissue repair cells intramuscular",
                              "tissue repair cells intraarterial",
                              "bone marrow stem cells intramuscular"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01065337"
                        ]
                  },
                  {
                        "Rank": 473,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo \"button (pellet)\" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic transplant of BM-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04545307"
                        ]
                  },
                  {
                        "Rank": 474,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Gene transfer to treat Hemophilia B"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: YUVA-GT-F901"
                        ],
                        "ArmGroupLabel": [
                              "YUVA-GT-F901"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03961243"
                        ]
                  },
                  {
                        "Rank": 475,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Gene transfer to treat Hemophilia A"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: YUVA-GT-F801"
                        ],
                        "ArmGroupLabel": [
                              "YUVA-GT-F801"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03217032"
                        ]
                  }
            ]
      }
}